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ABSTRACT
THE CONNECTION BETWEEN MARIJUANA, CIGARETTE SMOKING AND METABOLIC SYNDROME
AMONG ADULTS IN THE UNITED STATES

By
BARBARA A. YANKEY
MARCH 24, 2017
Under the direction of Ike S. Okosun, PhD

Background: Alcohol, marijuana and tobacco are the most common recreationally used
substances in United States (US). However, unlike alcohol and tobacco, marijuana is an illicit
substance. The increasing support for reclassification of marijuana as legal substance
necessitates investigating its effect on health. These studies seek to examine the relationship
of marijuana and tobacco with metabolic syndrome (a precursor of cardiovascular diseases the primary cause of morbidities and mortalities).
Method: Data from 2011 public-use linked mortality file of the National Center for Health
Statistics, Centers for Disease Control and Prevention, and 2005-2006 & 2011-2012 US National
Health and Nutrition Examination Survey was used to estimate the effect of marijuana and
tobacco on metabolic syndrome. Odds ratios from logistic regression analyses were determined
using four main diagnostic criteria for metabolic syndrome. Odds ratios were compared using:
National Cholesterol Education Program Adult Treatment Panel III, World Health Organization,
European Group for the study of Insulin Resistance and International Diabetes Federation
definitions of metabolic syndrome. Hazard ratios (HRs) for cardiovascular mortality were
estimated using cox proportional hazard regression.

Results: Each year of marijuana use was associated with increased odds of metabolic syndrome
[OR=1.05 (95% CI: 1.01, 1.09)] and hypertension [OR=1.04 (95% CI: 1.01, 1.07)]. Each additional
year of cigarette smoking was associated with increased odds of hypertension [OR=1.03 (95% CI:
1.00, 1.06)] and hyperglycemia [OR=1.03 (95% CI: 1.01, 1.05)]. Adjusted HR for hypertension
mortality for marijuana users compared to non-marijuana users was 3.42 (95% CI: 1.20, 9.79)
and 1.04 (95% CI: 1.00, 1.07) for each year of marijuana use.
Conclusion: Prolonged years of marijuana use was associated with increased odds of metabolic
syndrome and hypertension irrespective of the criteria used to define metabolic syndrome. Our
results also indicate that marijuana use is associated with increased risk for hypertension
mortality. The association between prolonged use of marijuana and risk of cardiovascular
morbidities and mortalities requires further investigation whilst developing global public health
policies regarding legalization of marijuana use.
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PREFACE
Initiation and continual use of recreational substances, is a complex process. Science continues
to investigate, project, inform and protect the populace from the deleterious effects of
substance use. The National Institute on Drug Abuse states that “In reality, drug addiction is a
complex disease, and quitting usually takes more than good intentions or a strong will. Drugs
change the brain in ways that make quitting hard, even for those who want to.”
Michael D. Lemonick in his article on the science of addiction opens with the statement, “For a
species wired for survival, we have an odd habit of getting hooked on things that can kill us.”
My dissertation was inspired by the many scenes of struggle as I travelled each day to school. I
could hear the cry for help, feel the need for health, the yearning for love, see the hand of
disparities. The question on my mind was simple; Why? Is it the search for joy? Is it curiosity? Is
it neglect? Is it the lack of knowledge or is it deception that drives initiation of substance use? I
came to the conclusion that the power still lies in knowledge; knowing the truth about the
effect of any substances on our system. The saying has been from of old: “For lack of
knowledge, people perish”
I find the words of Pope Francisco powerful for anyone struggling with substance use and ill
health. “You can have defects, be anxious and irritated sometimes. Live, but do not forget that
your life is the biggest company in the world. Only you can prevent your life from going into
decline. There are many who will appreciate, admire and love you. I would like you to
remember that, being happy is to stop being a victim of the problems and rather become an
actor of history itself. Use failure to sculpt serenity.”
“Quia non habuit scientiam gens pereat”
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CHAPTER 1
Literature Review
Marijuana and Cigarette Smoking as Recreational Substances
Recreational substances are substances that have the potential to alter consciousness
with a resultant pleasurable feeling. Reasons ascribed to the use of recreational substances span
primarily from actual relieve of depressing symptoms to curiosity and social acceptance. Some
recreational substances are commonly regarded as drugs because of their effect on the central
nervous system. They are classified as legal, illegal or controlled depending on their psychoactive
properties.
Tobacco (Nicotiana species) and Marijuana (Cannabis species) are two common
recreational substances whose main route of administration is smoking. Currently in the United
States, apart from alcohol, tobacco and marijuana are the most common substances of abuse
especially among adolescents (Latimer & Zur, 2010). The use of marijuana in adults is also
increasing especially among adults aged 25 years and above.
Smoking is a general term that describes the process whereby active substances are
delivered into the bloodstream via the lungs after inhaling smoke from burnt dried leaves.
Smoking is associated with certain cultures and practices and has been practiced way back in
5000 BC; it currently is a common route of recreational drug use.
Smoking is one of the leading causes of preventable death worldwide and a reversible
and modifiable factor for several morbidities. Smoking induces several physiological responses
that are not only carginogenic but cardiotoxic as well; research shows that smoking aggravates
atherogenesis (McGill, 1988). Smoking seems to find a way of sustaining its popular social
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practice despite evidence of its detrimental effects on health. Research conducted by Doll and
Hill initiated evidence into the carcinogenic effects of tobacco smoking on the lungs (Doll & Hill,
1950) and ultimately the first surgeon’s general report on smoking and health in 1964 (Smoking
& Health, 1964).
Smoking is hazardous to every organ of the body and the benefits of smoking cessation
interventions cannot be overstated (Anthonisen et al., 2005; Eriksen, Mackay, & Ross, 2013;
Kottke, Battista, DeFriese, & Brekke, 1988; Lemmens, Oenema, Knut, & Brug, 2008; Prochaska,
Delucchi, & Hall, 2004; West & Shahab, 2010). A review of the lung health study demonstrated
that smoking cessation reduces mortality from both lung cancer and coronary heart disease
(Anthonisen et al., 2005). Smoking cessation also improves lipid metabolism and cardiometabolic
factors (Gastaldelli, Folli, & Maffei, 2010). Most of these studies assessed tobacco smoking,
however research on the health effects of marijuana smoking is now evolving.

Recreational Substance Use in the United States
In the first century BC, the tobacco plant was used for medicinal, religious, and
recreational purposes (Newton, 2010). After several years of use, the deleterious effect of
tobacco on health and economic growth cannot be overstated and the impact of public health
measures towards smoking cessation and successes cannot be understated. The current
inclination towards legalization of marijuana questions the possibility of a replay of the journey
with tobacco (Falkowski, 2014).
The CDC reports that 17.8% of adults in the US were current smokers in 2013 with a
greater prevalence among men (20.5%) than women (15.3%). The highest current smoking rates
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were among non-Hispanic Multi-racials (26.8%) and non-Hispanic American Indians/Alaska
Natives (26.1%) with lowest rates among non-Hispanic Asians (9.6%).
Marijuana is classified as a Schedule I controlled substance under Federal law (Digest,
2014). Schedule I substances under the Federal Controlled Substances Act (CSA) are considered
as having a high potential for abuse and not having any currently accepted medical use in
treatment, consequently its use is reserved for very limited circumstances. Notwithstanding,
several States approve medical marijuana use and two States have legalized marijuana for
recreational use.
The World Health Organization (WHO) reports that the worldwide annual prevalence of
cannabis use is about 2.5%. The National Institute on Drug Abuse (NIDA) estimates that in the US
prevalence of current cannabis users aged 12 years and older, rose up to 7.3% in 2012 from 5.8%
in 2007. This escalation is attributed to the current trend towards legalization of marijuana.
As at 2013, 18 US states and the District of Columbia permitted medical use of marijuana,
with Colorado and Washington permitting its recreational use. Contributing factors to the
current move to legalize marijuana include the medical use of marijuana (Hoffmann & Weber,
2010). Additionally, some research support the argument that decriminalization of cannabis has
the potential to make law enforcement resources available to control certain trafficking activities
without increasing cannabis abuses (Single, E. et al., 2000). Research on the effects of chronic
use of marijuana is exigent if marijuana will universally be used recreationally.

3

Tobacco
Tobacco use is a very important modifiable lifestyle associated with preventable ill health
and premature mortality. Tobacco smoking is a major risk factor for many chronic diseases that
affect primarily the heart, liver and lungs. Tobacco is obtained mainly from the leaves o the plant
Nicotiana tobacum, though there are over 70 species of the plant. There are many formulations
of tobacco; common ones are cigarettes, cigar, snuff and kreteks to name a few.
The main active ingredient in tobacco is nicotine which is a stimulant. The primary mode
of administration is smoking. Nicotine binds to cholinergic nicotinic receptors and promotes the
release of several neurotransmitters. Nicotine is addictive and induces tolerance (Benowitz,
1998); this plays a factor in its chronic and incremental use among some people. This could also
play a competitive role with individual smoking cessation volition. Nicotine’s stimulant activity on
the sympathetic nervous system leads to increase in blood pressure and heart rate. High doses
can also lead to hypotension.
The popularity and spread of tobacco use was facilitated by major tobacco companies
who used several marketing strategies to make tobacco use especially smoking enticing and
even acceptable among women (for whom smoking was frowned upon). Smoking rates in the US
rose up to about 42% in the 1960’s and dropped starting 1965 after the first surgeon general’s
report on smoking and health to about 20.6% in 2008 (Dube, Asman, Malarcher, & Carabollo,
2009) and about 19.3% among adults aged 18 years and above (Control & Prevention, 2011).
The WHO estimates that in the early 1990’s about 1.1 billion people aged 15 years and
above worldwide smoked; equivalent to a third of the global population. The gender rates were
about 47% of males and 12% of females. It was estimated that the number of smokers may
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increase to about 1.64 billion by 2030 with a resultant increase in factors of poor health as well
as mortalities if no measures were taken to discourage smoking. Smoking cessation programs
have contributed greatly in reducing smoking prevalence rates. Overall global smoking
prevalence among people aged 15 years and above fell to 29% in 1995 (Jha, Ranson, Nguyen, &
Yach, 2002). In 2012, the estimated worldwide age-standardized prevalence of smoking among
this cohort was 31% for men and 6.2% for women, however there are regional disparities in
these smoking rates (Ng et al., 2014).
Doll and Hill demonstrated associations between smoking and lung cancer (Doll & Hill,
1950), several other studies which ensued confirmed similar findings. A 34 year follow up of
Framingham cohorts who were 30-62 years when they entered the study demonstrated that
cigarette smoking was associated with lung and cardiovascular disease: lung cancer, stroke,
ischemic heart attack etc. (Freund, Belanger, D'Agostino, & Kannel, 1993). It is an established
fact that smoking is associated with several health hazards (Eriksen et al., 2013; Slama, 2012).
Smoking is also characterized by premature and high mortality and cessation reverses ill health
(Jha et al., 2013).
Across all studies the benefits of smoking cessation is emphasized. Smoking cessation has
immediate and important benefits to all who stop smoking even after a short time, leads to
longer life span, decrease the risk for lung cancer and cardiovascular diseases (Critichley &
Capewell, 2007; General, 1990; Jha et al., 2013; Taylor Jr, Hasselblad, Henley, Thun, & Sloan,
2002).
There is evidence that tobacco use is associated with weight reduction and this has the
potential of discouraging smoking cessation among people who seek to fight or prevent obesity.
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Smoking may increase basal metabolism or reduce appetite and consequently may result in
reduced intake of food (Louis-Sylvestre, 1993). Weight gain and obesity are however not just a
direct cause of food or increased caloric intake. Obesity has multifactorial components and more
research is needed in this area to fully elucidate the effect of tobacco use not only on weight but
on the classification of obesity and among different populations.
Results of research on tobacco and weight distribution or classification are actually
not conclusive; some report that smoking increases abdominal obesity (Chiolero, Faeh, Paccaud,
& Cornuz, 2008) others that it decreases weight (Klesges, Meyers, Klesges, & LaVasque, 1989)
and others report the associations are weight definition dependent (Potter, Pederson, Chan,
Aubut, & Koval, 2004). Since body weight shares integrate properties with metabolic syndrome
and several chronic diseases, one area of interest is the effect of tobacco use (which is also
connected to several diseases and controversial with weight) on the metabolic syndrome.
Much as this is an understudied area for tobacco, available literature shows that smoking
has nonlinear relationships with factors of metabolic syndrome especially among moderate
smokers, but heavy smoking of 20 cigarettes or more daily leads to adverse levels of metabolic
factors which approach linearity (Fontes, Moshammer, & Elmadfa, 2012). Research shows that
smoking and even levels of serum cotinine consistent with environmental tobacco smoking is
associated with metabolic syndrome (Sun, Liu, & Ning, 2012; Weitzman et al., 2005). Tobacco
smoking is also associated with the lipid components of the metabolic syndrome;
hypertriglycerideamia (Oh et al., 2005; Reynolds et al., 2011), low HDL (Chen et al., 2008; Oh et
al., 2005).
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Smoking causes inflammation; it increases the production of pro-cytokines, reduces
levels of anti-inflammatory cytokines (Arnson, Shoenfeld, & Amital, 2010) and increases
pathologic levels of inflammation-sensitive proteins like alpa1-antitripson,fibrinogen etc. which
are associated with cardiovascular problems (Lind et al., 2004). Inflammation is a precursor to
several factors of the metabolic syndrome.
Smoking also reduces glucose tolerance and plasma insulin levels and demonstrates a
dose dependent relationship (Janzon, Berntorp, Hanson, Lindell, & Trell, 1983). A large cohort
study conducted by Will J. C. et al., and other prospective studies show that smoking is
associated with the incidence of diabetes and this was likely dose dependent as well (Kawakami,
Takatsuka, Shimizu, & Ishibashi, 1997; E. B. Rimm et al., 1993; Eric B Rimm, Chan, Stampfer,
Colditz, & Willett, 1995; Will, Galuska, Ford, Mokdad, & Calle, 2001).
Even though the relationship between smoking and body weight is complex, tobacco
smoking is most likely associated with increasing rates of metabolic syndrome. The NCEP ATP III
has emphasized that with increasing rates of obesity, metabolic syndrome is likely to have a
greater attributable impact than tobacco on premature death from coronary artery diseases (E.
S. Ford, Giles, & Dietz, 2002; S. Grundy et al., 2002; Program, 2001). This makes smoking and
metabolic syndrome very important subjects for public health if global health goals must be
achieved.

Marijuana and Medical Marijuana
Marijuana or cannabis is a leafy flowering plant that embraces three species; Cannabis
sativa, Cannabis indica and Cannabis ruderalis. Though cannabis is used orally, common route of
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administration is smoking after which it is readily absorbed in the lungs. Cannabis has
psychoactive properties and is a popular recreational substance because it induces relaxation
and euphoria to some extent.
Cannabis is also used medically in some settings; it has been used to relieve chronic and
neuropathic pain as well as nausea where conventional medications fail to provide relieve of
symptoms. Dronabinol and nabinol are medications of cannabis indicated for chemotherapy
associated nausea and vomiting. They are also used to manage anorexia associated with weight
loss in patients who have acquired immune deficiency syndrome. The use of cannabis is
however also associated with psychotropic and other adverse health effects.
The active ingredients of cannabis are known as cannabinoids; the major psychoactive
ingredient is Delta-9 tetrahydrocannabinol (THC). Cannabis exerts its effect on the
endocannabinoid system where they act on cannabinoid receptors. Cannabinoid receptors are
stimulated by endocannabinoids which are endogenous ligands. Cannabinoid receptors 1 (CB1)
and 2 (CB2) were discovered during the 1990’s and this has since increased interest in research
of cannabinoids. Apart from the brain, cannabinoid receptors and endocannabinoids are present
in peripheral tissues.
Absorption of cannabis can be erratic and differs in individuals. The plasma half-life of
cannabis is 20-30 hours. Cannabis can be detected in the urine for up to two months in a heavy
user but a few days in a rare user. In up to moderate doses, cannabis increases sympathetic
activity leading to tachycardia and increased cardiac output. At high dosage, cannabis increases
parasympathetic activity resulting in bradycardia and hypotension. Both the sympathetic and
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parasympathetic effects of cannabis can be life-threatening especially among people who have
underlying cardiac problems (Ghuran & Nolan, 2000; Olson, Anderson, & Benowitz, 2007).
Both CB1 and CB2 are involved in regulation of energy balance, appetite, insulin
sensitivity and lipid metabolism (Blüher et al., 2006; Engeli & Jordan, 2006; Pagotto, Marsicano,
Cota, Lutz, & Pasquali, 2006). Research support that the endocannabinoid system as well as
chronic smoking of cannabis are associated with metabolic irregularities like abdominal obesity
and insulin resistance (Blüher et al., 2006; Di Marzo, 2008; Kunos, 2007; Muniyappa et al., 2013)
as well as cardiovascular function (Cota, 2007; Pacher & Steffens, 2009).
Upon stimulation of CB1 receptors, the liver and adipose tissues respond through
lipogenesis, lipid accumulation and impairs insulin secretion and function or induces pancreatic
beta cell death (Kim et al., 2012; Sarker & Maruyama, 2003). Apart from endocannabinoids, the
psychoactive agent in cannabis, THC also stimulates CB1 and can induce glucose intolerance.
Cannabinoid receptors are important targets in pharmacology for managing obesity
(Bellocchio, Mancini, Vicennati, Pasquali, & Pagotto, 2006). Stimulation of CB1 receptors
increases appetite; the principle of managing obesity by using the pharmacologic agent
Rimonabant which is a CB1 receptor antagonist. Rimonabant is however central acting and
causes neuropsychological effects, thereby preventing its approval in the US and subsequent
withdrawal from several markets. CB2 receptors are also involved in metabolic changes
associated with diet, however stimulation of CB2 receptors improve glucose tolerance
(Bermudez-Silva et al., 2007) and seem to work in the reverse of CB1 stimulation.
Chronic use of cannabis no doubt is associated with metabolic health. A major problem
with the use of medical cannabis is standardization of the dose as well as an acceptable
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formulation. There are about 60 cannabinoids in cannabis aside so many other active substances
that have not been studied. Absorption of the active ingredients in cannabis is erratic and
specific to an individual’s physiologic make up which can lead to overdosing and poisoning. Also
the effect of the active ingredients in cannabis can be contradicting and unpredictable.
The endocannabioid system is involved in metabolic regulation, is a major target of
interest for managing obesity and indiscriminate use can lead to chronic detrimental health. It is
important to consider the long term effect of chronic and liberal use of marijuana on metabolic
and cardiovascular health among populations.

Metabolic Syndrome and its Genesis
Metabolic syndrome is the co-existence of delineated clinical and biochemical risk factors
that increases the propensity of having a cardiovascular disease or event by about three fold
(Isomaa et al., 2001). The genesis of work on factors associated with metabolic syndrome dates
back. It is noteworthy that the masterpiece of the Father of pathology, Joannes Baptista
Morgagni - ‘De sedibus et causis morborum per anatomen indagata’ published in 1765, initiated
the description of correlation between visceral obesity, high blood pressure and cardiovascular
disorders (Morgani, 1765). In 1947 the French physician Dr. Jean Vague published his work on
the finding that abdominal obesity is associated with diabetes and cardiovascular diseases
(Vague, 1947). He introduced the terminology android obesity to describe this condition.
During the late 1960s through 1970s, advances in technology and availability of
epidemiologic data permitted varied research on the metabolic syndrome. Several terminology
were used to describe the co-existence of its risk factors; metabolic trisyndrome and notable
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among them plurimetabolic syndrome. In 1988 Dr. Gerald Reaven described the common
clustering of dyslipidemia, hypertension and hyperglycemia as Syndrome X (Reaven, 1988). He
noted that Syndrome X was a multiple risk factor for cardiovascular diseases and implicated the
role of insulin resistance in Syndrome X, hence the term insulin resistance syndrome.

Metabolic Syndrome and Criteria for Research
The risk factors for metabolic syndrome are extensively documented, however a unifying
definition remains a challenge. The risk factors, its combinations or cut of points are varied for
different deliberative bodies; World Health Organization (WHO), European Group for the Study
of Insulin Resistance (EGIR), National Cholesterol Examination Program, Adult Treatment Panel III
(NCEP ATPIII) and recently criteria by the American Heart Association/National Heart, Lung and
Blood Institute (AHA/NHLBI) and the International Diabetes Federation (IDF). The new IDF
definition for metabolic syndrome is the presence of central obesity (ethnic specific waist
circumference values) and any two values of the following: hypertriglyceridemia, elevated blood
pressure, raised fasting plasma glucose or reduced levels of high density cholesterol. A previous
diagnosis of diabetes or medications for any of the listed conditions is also included. The
definition by NCEP ATPIII is commonly used in clinical practice because the factors are more
practical to measure.

Metabolic Syndrome, Epidemiology and Risk Factors
The worldwide prevalence of metabolic syndrome ranges from 10% to about 84%
depending on the definition used for metabolic syndrome or demographic composition of the
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population (Desroches & Lamarche, 2007; Kolovou, Anagnostopoulou, Salpea, & Mikhailidis,
2007). The National Health and Statistics Report shows that during 2003 to 2006, based on
NCEP/ATPIII guidelines, the prevalence of MetS in the United States was about 34% among
adults aged 20 years and above. In the general US population, the age adjusted prevalence of
MetS was estimated to have reduced from 25.5% in 1999 to 22.9% in 2010, however this
pattern of decrease is not evident in the prevalence of risk factors of the individual components
of MetS (Beltrán-Sánchez, Harhay, Harhay, & McElligott, 2013).
Obesity especially abdominal obesity is a major risk factor for metabolic syndrome, and
consequently a component of metabolic syndrome (Bray, 2007; Despres & Lemieux, 2006).
Obesity induces neuroendocrine abnormalities which affects various metabolic activities leading
to diabetes and cardiovascular diseases (Björntorp, 1992). Surging rates of obesity among
populations are associated with increasing MetS prevalence and incidence of chronic diseases
(Eckel, Grundy, & Zimmet, 2005; James, Rigby, & Leach, 2004).
Dyslipidemia, insulin dysfunction, and high blood pressure are the other determinants of
metabolic syndrome. Apart from increases in waist circumference, elevations in triglycerides and
blood pressure and are most attributable to increase in rates of metabolic syndrome especially
among adults (Earl S Ford, Giles, & Mokdad, 2004). Dyslipidemia promotes atherogenesis, which
is a major path to aberrations in cardiovascular integrity (S. M. Grundy, 1997). The role of insulin
dysfunction and hypertension in metabolic syndrome is demonstrated through their actions on
the sympathetic nervous system, leading to endothelial abnormalities and poor cardiovascular
function (Mendizábal, Llorens, & Nava, 2013).
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Among demographic characteristics, increasing age also predisposes one to a higher
tendency for metabolic syndrome. Progress in age is associated with several pathological
processes in the human system (S. M. Grundy, Brewer, Cleeman, Smith, & Lenfant, 2004)
including changes in tissue energy metabolism that could lead to lower resting metabolic rate
with advanced age (Fukagawa, Bandini, & Young, 1990).
Several studies show that MetS is more prevalent among men than women and this is
attributed to android or central obesity (Regitz-Zagrosek, Lehmkuhl, & Weickert, 2006), which is
more of a fat distribution pattern among men. Compared to gynoid obesity, android obesity
leads to cardiovascular diseases. The anti-atherosclerotic property of estrogen also plays a
protective role in the lower rates of MetS among women. This is evident in that fact that rates of
MetS increase among post-menopausal women in whom estrogen levels are low (RegitzZagrosek, Lehmkuhl, & Mahmoodzadeh, 2007; Tong et al., 2005). Yet, among those with MetS,
men still carry higher prevalence of cardiovascular diseases and mortality from other causes
irrespective of underlying diagnosis of diabetes or cardiovascular disorder (Kurl et al., 2006;
Lakka et al., 2002).
Social economic factors like education and income can change the relation between
MetS and gender (Loucks, Rehkopf, Thurston, & Kawachi, 2007). Education and increased
income generally acts favorably on metabolic factors. Among women those who are educated
are generally less likely than those who are not, to have the MetS; however this pattern is not
necessary so among men. This also applies to increased income; low income to poverty ratio is
associated with high MetS rates among women (Loucks et al., 2007). The impact of other factors
like marriage and place of birth on MetS are of research interest.
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Racial and gender specific differences exist with respect to MetS (Ervin, 2009; E. S. Ford
et al., 2002). Non-Hispanic White females are less likely than non-Hispanic Black and Mexican
American females to have MetS, whereas non-Hispanic White males are generally more likely
than non-Hispanic Black males to have MetS (Ervin, 2009). Ethnic differences in MetS rates, has
partly been explained by diet (Beydoun et al., 2008), socioeconomic and lifestyle factors which
contribute to obesity (Cossrow & Falkner, 2004) as well as genetic factors (Firmann et al., 2008)
or an integration of the environment with genetic factors (Benyamin et al., 2007). Other
physiologic factors like insulin resistance seem more prevalent among Hispanics, leading to a
higher rate of MetS among them (Li et al., 2006).
Among lifestyle factors, whereas reduced physical activity and fatty diet are evidently
associated with a higher risk for metabolic syndrome, the effects of alcohol and tobacco on MetS
are not conclusive (Lee, Jung, Park, Rhee, & Kim, 2005; Mayer, Newman, Quesenberry,
Friedman, & Selby, 1993; Eric B Rimm et al., 1995; Sacco et al., 1999; Santos, Ebrahim, & Barros,
2007). Yoon et al. however, conclude that heavy alcohol consumption is actually associated with
increased likelihood of having metabolic syndrome as a whole or some factors of the MetS
especially central obesity and hypertension (Y. S. Yoon, Oh, Baik, Park, & Kim, 2004).

Cigarette Smoking, Marijuana Use and Metabolic Syndrome
Although tobacco use has declined substantially in the United States, it remains the
second-leading cause of total deaths and disability. The perception of lower risk associated with
varied forms of substance use, can potentially lead to re-engagement or encourage initiation of
substance use. For example flavored cigarettes enticed adolescents to initiate smoking. The
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wrong notion that e-cigarettes are less harmful also encourages cigarette smoking. Legalization
of marijuana backed by information, that marijuana is beneficial or not associated with certain
diseases, or conditions that carry grave consequences on morbidity, disability and mortality like
metabolic syndrome, could potentially threaten public health gains, if ultimately it is
demonstrated not to be so. The scientific community, has the responsibility to protect the health
of the public, through sharing evidence-based information, or at least in the absence of evidence
exercise restraint in divulging information that could potentially be harmful in the long term. It is
still important to document and support tested evidence of any benefits of substance use.
Because recreational substances affect the brain and have psychoactive properties, if it
must be prescribed for ailments, monitoring must be available. It is necessary to invest resources
to investigate and address any benefits or harms associated with substance use. If marijuana
must be permitted for recreational use, the health system must be in readiness for the varied
aspects of the consequences of liberal recreational use of a substance that is psychoactive, has
erratic distributions and effects among different individuals and is comparatively understudied in
contemporary times. It is important to invest in investigations on marijuana use and the primary
cause of disabilities, morbidities and death, in the interest of sustaining public health gains in
cardiovascular disease prevention among the population and achieving sustainable health for
the populace.
Cardiovascular Morbidities and Mortalities
Cardiovascular disease (CVD) and stroke continue to be responsible for huge health and
economic burdens both in the US and globally, irrespective of the declining rates of mortalities
from CVDs. The American Heart Association report that a decline of 28.8% was observed in the
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US from 2003 to 2013. The 2013 overall rate of death attributable to CVD was 222.9 per 100,000
Americans with gender and racial-ethnic differences (Mozaffarian, Benjamin, Go, Arnett, Blaha,
Cushman, Das, de Ferranti, Després, & Fullerton, 2016). Non-Hispanic black males had the
highest death rates (356.7 per 100,000) compared to 246.6 per 100,000 for non-Hispanic Black
females. Generally, males had a higher death rate than females. The death rates were 269.8 for
males and 184.8 for females (Mozaffarian, Benjamin, Go, Arnett, Blaha, Cushman, Das, de
Ferranti, Després, & Fullerton, 2016).
The decline in CVD deaths are attributed to clinical and behavioral interventions
especially increase in physical activity, good diet and smoking cessation as well as surveillance on
cardiovascular health and its associated risk factors. Generally current cigarette smoking rates
among adults have declined. In 2014, the prevalence of adult current smokers was 16.9%
compared to 24.1% in 1998. Irrespective of the declining rates of cigarette smoking, CVD deaths
due to tobacco use are still ranked high; together smoking and exposure to secondhand smoke
are attributable for about one third of coronary heart disease mortalities (Mozaffarian,
Benjamin, Go, Arnett, Blaha, Cushman, Das, de Ferranti, Després, Fullerton, et al., 2016).
Hypertension is a major risk factor for cardiovascular, cerebrovascular and renal diseases.
Hypertension is an underlying factor for most cardiovascular and cerebrovascular mortalities as
well as disabilities and as such poses a major health burden. Hypertension is attributable for
almost 50% of all global deaths from stroke. Hypertension prevalence is expected to increase by
about 60% on the global level by 2025 if no measures are taken to prevent the demographic
expansion of hypertension among populations (Kearney et al., 2005). Interventions leading to
controlled blood pressure is thus important. It is noteworthy that about 17.3% of all
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hypertension cases are undiagnosed, and this carries grave consequences for those affected.
Apart from smoking cessation, the decline in stroke mortality is also a result of controlling
diabetes mellitus, hypercholesterolemia and hypertension.

Economic costs of cardiovascular disease and substance use
The American Heart Association (AHA) report that, estimated annual cost for CVD and
stroke during 2011-2012 was $316.6 billion, including $193.1 billion in direct costs (hospital
services, physicians and other professionals, prescribed medications, home health care, and
other medical durables). During this period, indirect cost associated with lost future productivity
due to premature deaths from cardiovascular diseases and stroke was $123.5 billion, the
heaviest economic burden compared to all other diseases (the estimated direct cost for all
cancer was $88·7 billion in 2011). The cost associated with addressing substance use in the US is
estimated at $600 billion dollars annually (Abuse, 2015)

Theoretical Basis of Substance Use and Prevention
Substance Abuse and Mental health Services Administration (SAMHSA) report that in
2014, about 10.2% of Americans used an illicit substance in the past 30 days. They were aged 12
years and above. This percentage was higher than that observed each year from 2002 to 2013.
Marijuana use is adjudged the main driver of the increased prevalence of illicit substance use,
22.2 million of the total 27.0 million people used an illicit substance in the past 30 days
(adjudged current users).
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Bandura’s social cognitive theory (Bandura, 1999) explains the initiation and maintenance of a
given behavior and has been used to explain smoking and drug related behaviors, as well as
incorporated in plans to assist prevention or cessation of substance use. By this theory,
cognitive, environmental and behavioral factors interplay to define substance use.
Cognitive factors explain how the individual’s mental capability and disposition allows
him/her to understand the effect of substance use on his/her system. The emotional coping
responses to the effect of substance use, the individuals behavioral capacity under the influence
of substance use as well as self-efficacy. Overall, outcome expectancies play a role in substance
use. If the individual expects beneficial outcomes from substance use, they are likely to start or
continue using substances. If the individual expects to have cure of an ailment from using
substances, he/she is likely to use it. Medical marijuana proponents attest to the fact that they
benefit from using marijuana, for example in treating severe vomiting or pain, that responds to
no other analgesics. People may smoke cigarettes because they find that it relieves their stress.
At the same time, people do abstain from tobacco or drugs after experiencing very bad effects of
substances. For example someone who suffers a cardiac arrest after substance use, and would
likely not want to use the substance again, having come to face the reality of possible death in
connection to substance use. For some self-efficacy plays a major role in deciding strongly to
abstain and giving up to the detrimental effects of the substance. The mental capability plays a
major factor. At times genetic dispositions can explain cognitive behaviors with regard to
substance use, whether an individual’s use of substances is predominantly because of dictates
ingrained in the genes.
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The environment is a major determinant of substance use. Environmental factors may
enhance or prevent substance use. Living in an environment where substance use is prevalent or
is the norm can support the use of substances. Generally people who live in environments where
substance use is prohibited or where laws prevent the use of substances are not likely to initiate
or continue the use of substances. Peer use of illicit substances or recreational substances can be
a major environmental factor. Policies that allow or disallow the use of substances can also be a
factor for substance use. For example, banning smoking in public areas, prevents smoking in
those areas even if an individual is a heavy smoker. He/she will have to look for the right
environment to smoke. Alternately, bars that allow smoking for example will attract not only
smokers, but continuation of smoking activity which an individual may have stopped for some
time because of enabling environment.
Behavioral factors considers the individuals reactions to conditions in the environment or
inputs from the environments. The individual is likely to use available information on marijuana
use to make decisions whether to use marijuana or not. Information and education play very
important roles in the choices we make. The duty of health professional is to make evidence based
information available in a way to help individuals make informed decisions on their health. If
marijuana use is beneficial like food, the information must be made available, if the use of
marijuana is detrimental the information must be made available. Underlying each of these factors
are constructs of the socio cognitive theory. The idea that marijuana use is safe seems to be
assimilated well by a majority of the public and in some cases even among health-care
professionals. This has contributed to the support for legalization of marijuana use not only
medicinally but recreationally.
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Constructs of the socio cognitive theory are behavioral capability, reciprocal determinism,
emotional coping responses, outcome expectations, self-efficacy, collective efficacy, observational
learning, incentive motivation, facilitation, self-regulation and moral disengagement.
Behavioral capability considers the basic knowledge an individual has on substance use and
the skills necessary to avoid substance use initiation or quit substance use. For example knowledge
on the biological effects of marijuana on the human system, knowledge about the nature of
marijuana and other substances, its use and adverse effects, helps individuals to make decisions
on its use. Skills necessary indulging or avoiding marijuana use depends on the knowledge. To a
large extent, health professionals must make information on substance use available to target
groups and the populace in general to help control substance use.
Reciprocal determinism, considers the interaction between individuals’ behavior and the
environment. Whilst the social environment affects individuals’’ behavior, the individual’s
behavior or actions also affects the environment in which he/she operates or chooses to live.
Whether people choose to live in environments that support marijuana use or live in environments
that do not support marijuana use depends on this interplay. Is it likely that states that legalize
recreational marijuana use will attract people who are prefer to use marijuana or is it likely that
people who live in states that legalize recreational marijuana are likely to accept and adopt the
use as well as put in more measures to sustain policies that support marijuana use and protect
people who use marijuana?
Emotional coping responses address the responses to environmental and emotional
stimulations or stressors. Coping responses are targeted towards achieving a mental wellbeing or
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physical wellbeing, however, these responses can be negative or positive depending on the
individual’s cognitive functions. An individual who is addicted to substances is likely to become
confrontative if he/she is denied access to substances. Dependence on addictive substances is a
major problem for health systems but has been capitalized by the respective companies as a
sales strategy because it ensures the continuous use of these products irrespective of the
adverse effects. Yet others harmed by substance use seek social support and enroll in
rehabilitation programs. Others are self-controlling enough in the face of being temptation to
avoid substance use, or control its use. Several coping mechanisms like distancing and positive
reappraisal have been described (Sudraba et al., 2015).
Outcome expectations describes an important factor in substance use behavior.
Generally when people expect to have health benefits from a product, they are more likely to
support its use and use it. Marijuana has been described as harmless in some publications, and
people who expect not to be harmed by using marijuana will most likely use marijuana for some
purpose. Medical marijuana is another reason why proponent s of marijuana use support its
legalization. The outcome expectations of marijuana use is a major subject of contemporary
debate. Yet others may use substances as an escape from reality. People who expect harms from
the use of substances are likely to avoid using them. If business entities expect gains from sales
of marijuana, they are likely to support its legalization and promote its sale. If state legislators
expect to curtail illegal sales of marijuana and reduced criminal activities with marijuana
legalization, they are likely to legalize marijuana use.
Self-efficacy is the confidence or belief an individual has in performing certain activities to
achieve an expected outcome. This is a very relevant construct of substance use abstinence,
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initiation, continuation or cessation. The level of self-efficacy determines the amount of energy
or resources an individual or system will invest in performing an activity to achieve a set
outcome.
Self-regulation is an individual’s ability to perform an activity. An individual may strongly
to decide quitting smoking or not use marijuana or any substances. Self-regulation involves how
an individual plans to attain health or benefits from an action either through avoiding situations
that may promote substance use, or staying strong and avoiding substance use even when it’s
available. Strategies used in self-regulation include goal setting, self-monitoring, self-reward,
self-instruction, social support enlistment and feedback or evaluation.
Incentive motivation is the strategic use of rewards for achieving a set goal for example
for not smoking for ten days, and punishments like withdrawal of some privileges for nonachievement of set goals. Motivational incentives have been used to assist people continue
cessation programs, for example by awarding them prices for attending programs or not using
substances or presenting urine samples for investigation to affirm abstinence from substance
use (Stitzer, Petry, & Peirce, 2010).
Observational learning includes involves role modelling, observing the outcomes of the
behavior of others and making informed decisions to abstain from a detrimental activity based
on positive role modelling. Cues can be used in observational modelling to reinforce behavior or
prevent certain behaviors. For example explicit pictures of harms associated with tobacco use on
cigarette packages prevents people from smoking.
Facilitation involves the provision of resources and tools to assist in positive behavior.
Public health educators and other health care professionals play an important role in facilitation.
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Availability of rehabilitation centers and medications to help manage and prevent substance
abuse are important facilitators. The environment can also serve as a positive or negative
facilitator. Environments that promote or support substance use can be negative facilitators.
Collective efficacy is the combined force of a group to help each other achieve goals.
Alcoholic Anonymous (AA) is a social group aimed at helping those who use alcohol heavily to
stay sober or avoid heavy drinking through character building and spiritual support (Hunt &
Azrin, 1973). When communities build solid trust, social capital and share healthy expectations,
they can avoid crimes and unhealthy behaviors (Farmer, 2014).
Moral disengagement concerns a way of action which ignores the harm that can be
caused to others through substance use. For example, individuals may neglect the effect of
second hand smoking by smoking in public places. They may neglect the harm they can cause to
others by using psychoactive substances and driving. Moral disengagement can be challenging
force in substance use, especially considering the harm it can cause others who do not engage in
unhealthy lifestyles. Not educating people on the harms of substance use, and supporting the
use of substances that could potentially be harmful to people, especially those are not selfefficacious can be classified moral disengagement.
Constructs of the theoretical basis of substance use, is strongly tied to the socioecological model of health: individual, interpersonal, organizational, community and policy levels
(Sallis, Owen, & Fisher, 2008). Each level of the socio-ecological model plays an important role in
substance use and in the prevention of substance use. Science, the health community and social
community must consider the health risks associated with recreational cannabis use and
implement measures to protect the health of society.
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Current evidence supports strategies to improve cardiovascular health. A three pronged
strategy to improve cardiovascular health, include a) individual –focused approach which target
lifestyle changes and treatment approaches, b) healthcare systems approach, which involves
resources to improve health behaviors and health care as well as encouragement, facilitation
and rewards for efforts by healthcare providers and patients towards health improvement and c)
population approach which target lifestyle and treatment among various populations.

Limitations in Research
Research on marijuana use and in combination with metabolic syndrome is evolving. Data
on marijuana use among all relevant age groups is scarce especially among the youth and
elderly; this limits the population coverage that can be investigated for marijuana use and its
effect on health.
Most research find no significant associations between marijuana use and metabolic
syndrome, whilst others present results showing that marijuana use is associated with reduced
values of some components of metabolic syndrome like blood glucose (Penner, Buettner, &
Mittleman, 2013).
While these studies have stated some limitations others have questioned the design of
the studies. Most studies on marijuana and metabolic syndrome are cross-sectional because the
interest in this relationship is now evolving and data availability is limited. Longitudinal research
on the relationship between marijuana and metabolic syndrome is scarce.
A major challenge with assessing marijuana use is the definition of marijuana use. Some
studies use reported marijuana use as ever use of marijuana, use of marijuana in the past 30
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days. The NHANES has variables that describe marijuana use based on having ever used
marijuana, marijuana use in past 30 days, number of joints of marijuana used, age at first use of
marijuana, and more recently (2011-2012), whether one has used marijuana regularly for the
past year. Unlike cigarette smoking, the status of marijuana use has not been explicitly defined in
literature. Also, information on cotinine, the active metabolite of nicotine from tobacco is
publicly available for analysis, but that of marijuana is not. This poses limitations in quantifying
marijuana use in research.
In assessing metabolic syndrome, definitions vary widely in literature because different
deliberative bodies have different criteria for metabolic syndrome. This poses a challenge even in
interpreting surveillance reports. The reported prevalence of metabolic syndrome is varies
depending on the definition used. Cutt-off points for components of metabolic syndrome are
also not unified.
Cardiovascular effects of marijuana is based principally on experiments with delta
tetrahydrocannabinol (THC) the active ingredients of marijuana. This is principally on animal
models and administered by other routes instead of smoking, unlike tobacco which has been
studied extensively in real like situations among human subjects.
Marijuana is known to have a chemical variability has not been studied extensively. The chemical
variability of marijuana, coupled with individual variations in smoking behavior, poses challenges
in presenting firm conclusions on results from studies on marijuana that have used uncontrolled
smoking observations (Jones, 2002). High potency marijuana is becoming readily available and
experiments on their effects with respect to health is limited.
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Studies on the effect of acute and chronic use of marijuana on specific biologic functions
including cardiovascular processes for example, atherosclerosis, lipid metabolism, endothelial
function, clotting function, and its sequelae are limited. Studies on cardiovascular effects of
marijuana among older people with existing cardiovascular or cerebrovascular disease are
limited. Generally, there is a need for studies on mortalities associated with marijuana use
among the populace as its recreational use becomes legalized.

Statement of Purpose
The use of recreational substances carries both health and economic consequences
which if not addressed could ultimately challenge global health developmental efforts. It is
integral for public health to investigate the varied health effects of the use of substances that
gain legal and liberal use. Tobacco and marijuana are two recreational substances used
commonly in the United States. Like tobacco, marijuana use could potentially gain global
acceptance with time. Tobacco remains a legal substance even though its detrimental health
effects have been proven extensively. Public health has undoubtedly achieved a lot in the area of
smoking cessation by improve the health of individuals who smoke as well as those exposed to
second hand smoking.
According to the US Federal Law, The Controlled Substance Act of 1970; there is a
penalty for any act of possessing, dispensing, and prescribing marijuana. However in 1996, some
14 States (California, Alaska, Oregon, Washington, Maine, Hawaii, Colorado, Nevada, Vermont,
Montana, Rhode Island, New Mexico, Michigan, and New Jersey) had an amendment to their
state laws that allowed people who had been diagnosed by certified licensed physicians as
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having debilitating medical conditions to use of marijuana as supportive therapy. Gradually
marijuana is gaining support for legalization of its recreational use.
A journey back in history recounts how research by Doll and Hill in 1950 found the
association between smoking, lung cancer and heart disease (Doll, R. and Hill, A. B., 1950) after
massive support for tobacco smoking. With great public health effort, research and legal battle,
this ultimately led to the Tobacco Master Settlement Agreement (MSA) in 1998 to address
tobacco related health-care costs. The current trend towards recreational use of marijuana could
possibly be another journey down the trend. Research on possible adverse health effects of
marijuana use is exigent.
Our research seeks to add to the geminating interest in research on metabolic syndrome
and substance use as an illuminating pathway to addressing recreational substance use and
factors associated with cardio-metabolic diseases, a major cause of morbidity and mortality. The
cardio-metabolic association with recreational substance use especially marijuana has not been
studied extensively, and this will be an exploratory study to add to emerging literature on
marijuana use.
We used data from National Health and Nutrition Examination Survey (NHANES); a
program purposed to evaluate the health and nutritional status of the United States population.
We conducted bivariate and multivariate analysis to estimate the relationship between tobacco
smoking and marijuana use and factors of/and the metabolic syndrome. Definition of metabolic
syndrome has varying criteria by different deliberative bodies. We also assessed effect of using
varying criteria to define metabolic syndrome on the relationship with tobacco smoking and
marijuana use.
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Our aim is to investigate the relationship between:
A) Tobacco and Marijuana use and factors of/and metabolic syndrome: Very few studies
have looked at especially the relationship between marijuana use and metabolic
syndrome. With the burgeoning interest in marijuana use, empirical studies on its impact
with metabolic activity can be a pathway for describing chronic disease concerns related
to its use.
B) Tobacco and marijuana use with metabolic syndrome using the different criteria for
metabolic syndrome: Identifying a unified criterion for metabolic syndrome is still a
challenge. Different authorities in health give different criteria and cut-offs for metabolic
syndrome which could affect conclusions from studies. We plan to investigate the
relationship of tobacco and marijuana smoking under the different criteria for metabolic
syndrome and describe any differences in conclusion that may surface.
C) Marijuana use and cardiovascular health: The detrimental effects of tobacco on
cardiovascular health are well studied, however that of marijuana is currently scarce. We
will examine the relationship between marijuana use and mortality from cardiovascular
diseases using the NHANES public-linked mortality data.
Research Question/Hypothesis
Our research question of interest is: a) is recreational substance use (Tobacco or
Marijuana) associated with the metabolic syndrome? b) Using the different criteria for metabolic
syndrome, are there significant differences in diagnosis of metabolic risk between people who
engage in use of these recreational substances and people who do not? c) Do the additional
criteria for metabolic syndrome proposed by the International Diabetes Federation (IDF) tell a
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different story among those who use recreational substance and those who do not? d) Is the
use of marijuana associated with mortality from a cardiovascular disease?
For the purpose of this study, we assume the hypotheses that: a) those who use/smoke
tobacco and/or marijuana have increased odds for having risk factors of the metabolic syndrome
than those who do not, b) the different criteria for metabolic syndrome equally predict
metabolic risk factors among people who smoke tobacco or marijuana without significant
differences, and c) marijuana use like tobacco use is associated with high risks of mortality from
a cardiovascular disease.

Data
National Health and Nutrition Examination Survey (NHANES)
National Health and Nutrition Examination Survey (NHANES) started in 1960 and is a major
program of the National Center for Health Statistics (NCHS), under the Centers for Disease
Control and Prevention (CDC). The aim of the survey is to assess the health and nutritional status
of civilian noninstitutionalized US population. Since 1999, NHANES is a continuous program
which uses interviews and physical examinations for its purposes to assess the health and
lifestyle indicators of a nationally representative sample of about 5000 US adults and children.
After modifying the sampling technique employed for several iterations of data collection,
NHANES adopted a continuous “rolling” sample approach in 1999; selection is done through
complex, multistage probability sampling. Each year, the survey is conducted in 15 counties
across the US. Interviews are conducted by physicians and other healthcare professionals in
participant’s homes and examinations conducted in a mobile center.
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National Health and Nutrition Examination Survey (NHANES III) Linked Mortality File – Public-use
File
The NCHS has a mortality linkage to NHANES III. This linkage is with the death certificate data from the
National Death Index (NDI). The linked mortality file provides information on mortality among NHANES III
participants from 1988 to 2006. The mortality information is based on probabilistic match between
NHANES III and NDI death certificate records. The linked mortality file has a public-use and a restricted-use
file. The public-use file provides information on a limited set of mortality variables for adults of the
NHANES III survey, whilst the restricted-use file has more detailed mortality information and mortality
follow-up for children.
The public-use linked mortality file has information on the mortality status of adult participants
(CDC, 2015). Mortality information on participants is obtained from death certificates or probabilistic
matching from the National death index (NDI). The NHANES coded causes of death occurring in the US
before 1999 are based on the 9th revision of the International Statistical Classification of Diseases, Injuries,
and Causes of Death (ICD-9) guidelines and cause of death occurring since 1999 on the 10th (ICD-10)
revision. Causes of deaths occurring before 1999 were subsequently recoded into comparable ICD-10
rubrics. All deaths are classified as due to diseases of the heart (001), malignant neoplasms (002), chronic
lower respiratory disease (003), accidents-unintentional injuries (004), cerebrovascular diseases (005),
Alzheimer’s diseases (006), diabetes mellitus (007), influenza and pneumonia (008), nephritis, nephrotic
syndrome and nephrosis (009) and all other causes (010). Those assumed alive, ineligible for follow up,
aged below 18 years or have no cause of death available are left blank and un-coded.

Independent Variables
Our main independent variables are a) marijuana use and b) tobacco use. Tobacco use is assessed under
smoking-cigarette use whilst marijuana use is assessed under drug use by NHANES.
For smoking, all participants aged 12 years and above are eligible. Participants aged 12 -19 years
answered the questions at a mobile examination center using the Audio Computer-Assisted Self-Interviewing
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(ACASI) system in English and Spanish. Participants aged 20 years and above answered the questions at
home. They were interviewed by trained interviewers using the Computer-Assisted Personal Interviewing
(CAPI) system. The ACASI and CAPI have built in consistency checks to reduce data entry errors.
Participants who are aged 12 to 69 years are eligible to be asked about their lifetime or current drug use.
The participants administer a drug use questionnaire during an interview at a mobile examination center
(MEC). In the publicly available data file, only information from participants aged 18-69 years are included.
Adults aged 18 years and above self-administer the questions using Audio computer-assisted selfinterviewing (ACASI) system. The ACASI system allows respondents to listen to and answer questions at their
own speed. If an answer is entered that is programmed to be an error in the system, the respondent is
prompted by the system to correct the response before proceeding. Participants are reminded that their
answers are strictly confidential.
Smoking or Tobacco Use
For smoking/tobacco use, participants were asked a) “have you smoked at least 100 cigarettes your
entire life?” Answers given yes or no will be used for analysis, b) age at regular smoking, “How old were you
when you first started to smoke cigarettes fairly regularly?” Answers in range of years. Those who have never
smoked are coded as zero. Those who refused to answer or did not know were not included in the analysis,
c) current and continued use of cigarettes, “do you now smoke cigarettes?” We will include the answers
every day, some days or not at all. Current smokers are those who have smoked at least 100 cigarettes in
their life time and still smoke either every day or some days.
Marijuana Use
For marijuana use, participants are introduced to the description of marijuana and asked about their use
of marijuana. “Marijuana is also called pot or grass. Marijuana is usually smoked, either in cigarettes, called
joints or in a pipe. It is sometimes cooked in food. Hashish is a form marijuana that is also called ‘hash.’ It is
usually smoked in a pipe. Another form of hashish is hash oil. Have you ever even once used marijuana or
hashish?” We will only include participants who answered yes or no. Participants who refused to answer, or
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said they did not know or any missing information will be excluded from the analysis.
Other questions on marijuana use include a) age at first use of marijuana; “how old were you when you
the first time you used marijuana or hashish?” Answers in range of values in years, b) regular use of
marijuana; “have you smoked marijuana or hashish at least once a month for more than once a year?”
Answered as yes or no, c) age at regular use of marijuana; “how old were you when you started smoking
marijuana or hashish at least once a month for more than one year?” Answers in range of values in years, d)
frequency of marijuana use; “during the time that you smoked marijuana or hashish, how often would you
usually use it?” Answers are categorized as once a month, 2-3 times a month, 4-8 time a month, 9-24 times a
month, or 25-30 times a month, d) number of days they used marijuana in a month; “during the past 30
days, on how many days did you use marijuana or hashish?” Answered as a range of values, from 1 to a
maximum of 30, e) number of pipes or joints smoked daily; “during the time that you smoked marijuana or
hashish, how many joints or pipes would you usually smoke in a day?” Answered as 1per day, 2 per day, 3-5
per day, or 6 or more per day.
Control Variables
In our model, we controlled for demographic and lifestyle variables that confound the relationship
between our main independent variables and dependent variable. One drug question of interest is whether a
participant had ever used any other illicit/recreational drug, since these could be used jointly with marijuana;
“Have you ever used cocaine, crack cocaine, heroin or methamphetamine?” The answers were yes or no. We
used this as a control variable, where it was found to be confounding in the relationship between marijuana
and metabolic syndrome.
Questions on demographic indicators are asked by trained interviewers at home using the CAPI system.
Unlike those under16 years, who may need a proxy, participants who are 16 years and older are interviewed
directly. They chose the language of preference, either English or Spanish.
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Age
Age is related to cardiovascular health and no doubt metabolic syndrome as well as substance use. Some
age categories highlight this relationship. We used age as a dichotomous variable because of the effect of
age transition on substance use and metabolic health based on literature. In the NHANES, participants are
asked to give their age in years at the time of survey.
Gender
Gender differences affect cardiovascular health as well as smoking and substance use. Males generally
are more likely to use recreational substances than women do. Hormonal factors affect the cardiovascular
health of men and women differently. Participants stated their gender as males or females.
Education
Education is related to metabolic syndrome factors and substance use. Generally, more educated people
can afford healthier choices which positively affect cardiovascular health and this could be a confounder in
our model. In NHANES, participants are asked “what is the highest grade or level of school you have
completed or the highest degree you have received?” the answers are ranked as a) less than 9th grade, b) 9th11th grade (as well as 12th grade with no diploma), c) High school grade or GED or equivalent, d) some college
or AA degree and e) college graduate or above. We included education at an in interval level to control for
the effect of each level rise in education in the model.
Race and Ethnicity
In NHANES, participants are asked to identify themselves with the race/ethnicity they belong. They are
listed as Non-Hispanic Whites, Black, Asians, Mexican Americans, Other Hispanics and Multiracials/or people
of Other-Race. We used race as dummy variables with Non-Hispanic Whites as the reference.
Country of Birth
We controlled for country of birth. This is dichotomized as born in USA or other. In the survey,
participants are asked; “In what country were you born?” The responses are a) born in any of the 50 states of
the USA or Washington DC and b) other (born in another country). Place of birth may be associated with
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cardiovascular health, through the effectiveness of healthcare systems available that target, investigate or
control these conditions at an earlier stage in life. Generally, rates of obesity are also higher among people
born in US and this impacts metabolic syndrome rates. With respect to smoking, epidemiologic data shows
that the prevalence of smoking is quite high in the USA, even though it is dropping due to smoking cessation
interventions. Also, prevalence of marijuana use is high in the USA. We include country of birth as a
confounder with respect to cardiovascular and metabolic health.
Income to Poverty Ratio
We controlled for the ratio of family income to poverty (PIR). Income is a major factor for cardiovascular
health and as well as substance use. Generally, having a higher PIR is associated to better cardiovascular
health, because of affordability for healthcare services and healthier lifestyle choices including dietary
choices. Also, people who have a low PIR may engage more in substance use than those with a high PIR.
Several explanations have been given for this relationship and could be the vice versa; drug use leads to
poverty people may lose their jobs, alternatively, people who find themselves living in poor environments
are often surrounded by drug users and may easily obtain drugs on the streets and become substance users
themselves for several reasons. In the NHANES, PIR is recorded as a range of values from 0-4.9 and 5 for
those whose PIR are either 5 and above. Respondents report the total annual income for the entire family in
dollars. With this information, the PIR is calculated using the Department of Health and Human Services
(DHHS) poverty guidelines. No ratios are computed if income data is missing. We will use variable as a
continuous variable and assess the effect of each point rise in PIR or interval variable of: 0 to 1.0, 1.1 to 2.0,
2.1 to 3.0, 3.1 to 4.0, 4.1 to 4.9, and 5.0 and above.
For lifestyle factors, we controlled for alcohol use, physical activity and diet including other drug use.
Alcohol Use
Participants are asked about their lifetime and past 12 months’ alcohol use, irrespective of the type of
alcohol use. They are asked how often they had an alcoholic beverage in the past 12 months. We computed
number of alcohol drinks per week and assessed on a continuous level.
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Physical Activity
Participants are assessed for physical activity based on the Global Physical Activity Questionnaire (GPAQ).
Participants are asked if apart from work and transportation activities, they engage in at least ten minutes of
continuous a) vigorous or b) moderate recreational physical activity in a typical day. Those who respond no
to moderate physical activity were classified as not physically active and those who respond yes as physically
active.

Statistical Analysis
We conducted statistical analysis using SPSS and STATA packages.
To estimate the relationship between factors of/metabolic syndrome and recreational substance use.
We conducted bivariate and multivariate analysis. We estimated the odds ratios for having unhealthy levels
for any factor of /the metabolic syndrome among those who smoke tobacco, marijuana or both.
Model of bivariate analysis:
Y

Y

Y

Y

= b + b (cigarette smoking)

component of MetS

0

1

= b + b (marijuana use)

component of MetS

0

1

= b + b (cigarette smoking + marijuana use)

component of MetS

0

1

= b + b (iv )

MetS

0

1

1

Model of multivariate analysis:
Y

component of MetS

Y

MetS

= b + b (iv ) + b (iv ) + ……+b (iv )
0

1

1

2

2

k

k

= b + b (iv ) + b (iv ) + ……+b (iv )
0

1

1

2

2

k

k

Note: iv = independent variable
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For analysis by different criteria for metabolic syndrome, we assessed how the different criteria alters
our diagnosis of metabolic syndrome. We estimated the odds ratios for having metabolic syndrome among
those who smoke marijuana or tobacco compared to those who do not and assessed if there are any
differences based on the different criteria.
Model for bivariate analysis by metabolic syndrome criteria:
Y

= b0 + b1(iv)

Y

= b0 + b1(iv)

Y

= b0 + b1(iv)

Y

= b0 + b1(iv)

MetS(ATPIII)
MetS(WHO)
MetS(EGIR)
MetS(IDF)

Model for multivariate analysis by metabolic syndrome criteria:
Y

MetS(criteria)

= b0 + b1(iv) + b2(iv2) + ……+b (iv )
k

k

To estimate mortality from a cardiovascular disease attributable to marijuana or tobacco use. We
used Cox proportional hazard regression to estimate the effect of marijuana use on cardiovascular mortality.
We estimated hazard ratios to describe the relative risk of having a cardiovascular associated mortality. We
used Nelson-Aalen curves to describe findings.

Model for survival analysis:

H(t) = H (t) x exp (b (iv ))
0

1

1

H(t) = H (t) x exp (b (iv ) + b (iv ) + ….+ b (iv ))
0

1

1

2

2

k

k
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Aim: To assess the relationship between marijuana use, cigarette smoking and metabolic syndrome
among adults in the United States who reported they use marijuana or cigarettes in comparison to nonmarijuana and non-cigarette users.
Method: We conducted multiple logistic regression analyses using data from the 2011–2012 United States
National Health and Nutrition Examination Survey to estimate relationships between cardio- metabolic
risk factors and increasing years of smoking cigarette or marijuana use. Statistical adjustments were made
for both demographic and endogenous factors related to recreational substance use.
Results: Each year increase in marijuana use was signiﬁcantly associated with increased odds of metabolic
syndrome (OR = 1.05; 95% CI: 1.01, 1.09), and hypertension (OR = 1.04; 95% CI: 1.01, 1.07) adjusting
for both demographic and endogenous factors related to recreational substance use. Each year increase
in cigarette smoking was signiﬁcantly associated with increased odds of hypertension (OR = 1.03;
95% CI: 1.00, 1.06) and hyperglycemia (OR = 1.03; 95% CI: 1.01, 1.05) after adjusting for confounders.
Conclusion: The results of this investigation suggest that increased years of marijuana or cigarette use are
important factors in metabolic health; and consequently calls for the need to consider the potential
negative effects of marijuana or cigarette for metabolic syndrome and its associated cardio-metabolic
risk components.
© 2016 Diabetes India. Published by Elsevier Ltd. All rights reserved.

1. Introduction

burgeoning support for marijuana legalization as a recreational
substance be supported by evidence and research. Indeed, the
increase in support for recreational use of marijuana in the US calls
for an understanding and proper documentation of the nature of
the association between marijuana use and conditions associated
with diseases that have high rates of morbidity and mortality,
including metabolic syndrome (MetS).
Metabolic syndrome is a complex disorder deﬁned by a cluster
of interrelated factors that increase the risk of cardiovascular,
atherosclerotic diseases and type 2 diabetes. Described originally
by Hanefeld and Leonhardt [8] and popularized by Reaven [9],
MetS remains a subject of considerable curiosity because of the
complexity of the pathophysiology. The main components of MetS
are abdominal obesity, elevated arterial blood pressure, dysregulated glucose homeostasis, and dyslipidemia [10].
In this study we examined the relationship of recreational
substance use, speciﬁcally cigarette and marijuana with MetS.

Cigarette smoking and marijuana (cannabis) use are two
common recreational drug behaviors in many societies including
the United States (US). While cigarette smoking is a modiﬁable risk
behavior that is often linked to several chronic diseases [1], little is
known about the true relationship between marijuana use and
chronic disease conditions [2]. In the US, public opinion for
marijuana seems to be changing to legalization with respect to its
use for recreational purposes [3,4]. The use of marijuana for
medical reasons [5–7] has elevated public support for its
decriminalization. It is of importance to public health that the

* Corresponding author.
E-mail addresses: byankey1@student.gsu.edu, byankey1@outlook.com
(Barbara N.A. Yankey).
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2.4. Main independent variables

While some research exist on the effect of cigarette use on MetS
[11,12], very little exist on the relationship between marijuana use
and MetS, including its components. An underlying reason for
investigating the connection between marijuana and metabolic
syndrome is that cannabinoid receptors (the cell membrane
receptor for active constituent of marijuana) and endocannabinoids (endogenous ligands) are present in the peripheral tissues
that are involved in energy regulation and homeostasis [13– 15].
Importantly, Delta-9-tetrahydrocannabinol (THC), the main
active constituent of marijuana, acts on these cannabinoid
receptors [16]. If an important relationship between cannabis
and metabolic syndrome exists, its explication may help to lessen
the future burden of cardiovascular diseases.

Participants who answered no to the question ‘‘have you ever
used marijuana?’’ were categorized as never marijuana users.
Those who answered yes (had ever used marijuana), and
answered no to the question, ‘‘have you smoked marijuana or
hashish at least once a month for more than a year?’’ were
categorized as non-regular marijuana users and those who
answered yes as regular marijuana users. Other questions on
marijuana use include: Age at ﬁrst use of marijuana (‘‘how old
were you the ﬁrst time you used marijuana or hashish?’’) and Age
at regular use of marijuana (‘‘how old were you when you started
smoking marijuana or hashish at least once a month for more than
one year?’’). We calculated years of marijuana use by subtracting
age at regular marijuana use from the current age of participants.
Participants who were non-regular or never users had zero for the
number of years of marijuana used. For quantity of marijuana
smoked, participants answered the question: ‘‘during the time
that you smoked marijuana or hashish, how many joints or pipes
would you usually smoke in a day?’’ The answers were 1 per day,
2 per day, 3–5 per day, or 6+ per day. We used this as the quantity
of marijuana used per day and assigned never users or non-regular
users ‘‘zero’’ use per day.
Our other independent variable of interest is cigarette
smoking. Participants were asked, ‘‘Have you smoked at least
100 cigarettes your entire life?’’ We coded those who answered
no as non-smokers. For current use of cigarettes, participants
who said they have smoked at least 100 cigarettes in their entire
life, were asked ‘‘do you now smoke cigarettes?’’ We coded those
who said not at all as past smokers and those who said every day
or some days as current smokers (current smokers are those who
have smoked at least 100 cigarettes in their life time and still
smoke either every day or some days). To know the age at regular
smoking, participants were asked, ‘‘How old were you when you
ﬁrst started to smoke cigarettes fairly regularly?’’ We coded years
of smoking cigarettes for those who have never smoked as zero
and did the subtraction for current smokers. Those who refused
to answer or did not know were not included in the analysis.

2. Data and method
2.1. Data source
This study used data from the National Health and Nutrition
Examination Survey (NHANES). The NHANES is a major program of
the National Center for Health Statistics (NCHS), under the Centers
for Disease Control and Prevention (CDC) that assesses the health
and nutritional status of the US population. Since 1999, NHANES
enrolls approximately 5000 persons from 15 counties across the US
yearly for interview and examination. The enrollment is based on a
continuous nationally representative and complex sampling
method.
2.2. Inclusion criteria
This study was restricted to participants of 2011–2012
NHANES. Only subjects aged 20 years and above who responded
to the question on our main independent variable, ‘‘Have you ever
even once used marijuana or hashish?’’ were eligible for this study.
2.3. Dependent variables
Our main dependent variable is metabolic syndrome (MetS).
We also analyzed each of the individual components of MetS
separately. We classiﬁed MetS using deﬁnitions by the National
Cholesterol Education Program, Adult Treatment Panel III (NCEP,
ATP III) 2004 modiﬁcation, which adapts the International
Diabetes Federation (IDF) deﬁnition for hypertension and diabetes. Participants considered as having hypertension had an
average blood pressure above 130/85 mmHg or were on
antihypertensive medication. We used an average of the recorded
blood pressure readings as the value of an individual’s blood
pressure for the purpose of our study. Details on blood pressure
measurement
are
described
(http://www.cdc.gov/nchs/
nhanes/nhanes2009-2010/current_nhanes_09_10.htm).
Participants with fasting plasma glucose of 100 mg/dl or on some
antidiabetic treatment including insulin were coded as having
diabetes. The NHANES has a detailed description of laboratory and
examination procedures listed on (http://www.cdc.gov/nchs/
nhanes/nhanes2011-2012/manuals11_12.htm). Abdominal obesity was coded as yes for females with waist circumference of
more than 88.0 cm and yes for males with waist circumference
of more than 102.0 cm. Females with plasma High Density
Lipoprotein Cholesterol (HDL-C) of less than 50 mg/dl and males
with less than 40 mg/dl were coded as having low HDL-C.
Hypertriglyceridemia was coded yes for all participants with
plasma triglycerides of 150 mg/dl and above. Participants with
three or more of the components of metabolic syndrome
(abdominal obesity, hypertension, hyperglycemia, hypertriglyceridemia and low HDL-C) were coded as having metabolic
syndrome.

2.5. Control variables
For our control variables, we dichotomized age as above 25
years or below and compared with those above 25 years. This is
based on the effect of this age transition on metabolic syndrome,
speciﬁcally, aging and oxygen uptake during physical activity.
Research shows that from age 25 years to age 65 years, the
maximal intake of oxygen reduces by almost 5 ml per kg per min
[17]. In analyzing the effect of our main independent variables on
metabolic syndrome and its factors, we found it important to
consider this factor. Gender was categorized as male and female.
We compared other racial ethnic groups (Non-Hispanic Blacks,
Mexican Americans, other Hispanics, Asians and other Races) with
non-Hispanic Whites. We included education on an increasing
level as laid down by NHANES (Tables 1a and 1b). We
dichotomized physical activity as participation in at least
moderate physical activity (at least 10 min of continuous daily
recreational activity apart from all other activities) or not.
2.6. Control variables endogenous to recreational substance use
Married participants were compared to all other participants in
other marital categories listed in NHANES. Poverty to income ratio
was classiﬁed on an increasing level (Table 1a). Weekly frequency
of alcohol intake as reported by participants was estimated and
included in the model on an increasing level. Response to the
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Table 1a
Demographic characteristics of participants by cigarette smoking and marijuana use status.
Variable

Sample size, (%)

Cigarette smoking
Status, %

Marijuana use
Status, %

Current

Past

Never

Regular

Non-regular

Never

Gender
Male
Female

1499 (50.87)
1552 (49.13)

28.88
19.01

14.54
18.83

52.29
66.44

32.11
20.03

25.77
28.44

39.65
54.21

Race
Non-Hispanic Whites

1113 (36.46)

31.09

20.49

48.43

32.70

33.51

33.78

Non-Hispanic Blacks
Mexican Americans
Other Hispanics
Asians
Other Race

793 (25.99)
329 (10.78)
281 (9.21)
427 (14.00)
108 (3.54)

25.00
16.72
18.15
11.94
29.63

11.74
19.15
19.22
13.11
14.81

63.26
64.13
62.63
74.94
55.56

31.48
15.81
19.57
7.96
40.74

25.66
23.10
21.71
18.74
28.70

42.86
61.09
58.72
73.30
30.56

Marital status
Married
Never married
Widowed
Divorced
Separated
Living with partner

1371 (44.94)
920 (30.15)
42 (1.38)
275 (9.01)
123 (4.03)
320 (10.49)

18.67
23.18
35.71
33.09
33.33
36.56

19.91
11.64
23.81
22.18
10.57
14.37

61.42
65.18
40.48
44.73
56.10
49.06

20.00
28.48
35.71
33.45
22.76
39.81

27.52
28.26
23.81
29.82
25.30
20.06

52.48
43.26
40.48
36.73
52.03
40.13

Country of birth
USA

2154 (70.65)

28.84

16.77

54.39

34.06

31.88

34.06

895 (29.35)

12.51

16.54

70.95

7.26

15.31

77.43

149 (4.88)

Other countries
Education
<9th grade
9th to 11th grade
High school graduate
Some college/AA degree

22.82

22.15

55.03

12.75

8.72

78.52

(13.21)
(20.32)
(33.04)
(28.55)

42.43
33.28
24.90
8.15

18.11
16.64
15.97
16.07

39.45
50.08
59.13
75.77

35.82
33.12
29.07
15.73

19.90
21.65
30.85
32.84

44.28
45.23
40.08
51.44

543 (17.80)

20.85

6.64

72.51

29.83

28.55

41.62

758 (24.84)
1015 (33.37)
735 (24.09)

26.25
24.14
23.95

15.17
16.85
25.58

58.58
59.01
50.48

29.50
22.76
24.76

28.04
26.80
25.17

42.46
50.44
50.07

753 (26.39)

34.79

13.94

51.26

32.49

24.10

43.41

1048 (36.73)
555 (19.45)
497 (17.42)

27.79
15.32
10.06

17.19
17.48
19.72

55.01
67.21
70.22

28.91
19.28
20.52

24.24
33.51
33.80

46.85
47.21
45.67

403
620
1008
871

:::College graduate
Age groups (years)
20–25
26–35
36–49
50–60
PIR
<1.00
1.00–2.99
3.00–4.99
>5.00

Percentages are row percentages. Chi square tests (p-values not included in table) showed signiﬁcant differences among the various groups by smoking and marijuana use
status. PIR = Family income to poverty ratio.
Table 1b
Clinical and laboratory characteristics of participants by cigarette smoking and marijuana use.
Variable

Clinical examination
High WC
High blood pressure
Laboratory investigation
High FPG
High Serum Triglycerides
Low Plasma HDLC
Components of MetS
Waist circumference, cm
SBP, mm Hg
DBP, mm Hg
FPG, mg/dl
Serum triglycerides, mm/dl
HDL cholesterol, mm/dl

Sample size

Overall percentage

Current smoking
Status, %

Marijuana use
Status, %

Current

Past

Never

Regular

Non-regular

Never

2996
3051

49.80
33.53

22.65
26.00

18.57
20.33

58.78*
53.67***

25.49
26.13

26.43
26.03

48.09
47.85

3051
3051
3051

20.88
18.32
39.63

24.96
26.65
27.79

20.57
21.47
16.46

54.47**
51.88***
55.75***

25.47
26.12
24.75

25.63
28.09
26.66

48.90
45.80
48.59

1338
1325
1325
1355
1341
1342

Average ± SE
97.8 ± 0.8
118.6 ± 0.8
71.9 ± 0.6
101.6 ± 1.1
132.2 ± 6.4
51.7 ± 0.6

98.4 ± 0.9
121.7 ± 1.7
71.8 ± 1.0
102.2 ± 1.4
149.1 ± 6.6
49.8 ± 1.3

99.8 ± 1.8
119.9 ± 1.6
73.9 ± 1.0
104.6 ± 3.3
135.2 ± 9.8
52.3 ± 1.1

97.1 ± 0.8***
117.0 ± 0.9***
71.2 ± 0.7***
100.6 ± 1.4
124.8 ± 6.4***
52.3 ± 0.5**

98.5 ± 1.4
120.3 ± 1.6
72.0 ± 0.8
102.6 ± 2.9
139.2 ± 8.1
50.9 ± 1.2

97.7 ± 1.1
117.3 ± 0.9
72.3 ± 0.8
101.5 ± 1.5
124.2 ± 8.2
52.1 ± 0.9

97.5 ± 0.8*
118.2 ± 0.9*
71.5 ± 0.8
101.01 ± 1.2
133.0 ± 9.1
52.1 ± 0.6

Tests of signiﬁcance for row percentages are based on chi-square tests, for continuous variables are F-tests and averages shown are weighted averages. WC, waist
circumference; FPG, fasting plasma glucose; HDCL, high density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; *Signiﬁcance at <0.05;
**Signiﬁcance at <0.01; ***Signiﬁcance at <0.001 for row differences.
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question ‘‘have you ever even once used (a) cocaine, (b) heroin or (c) methamphetamine?’’ was dichotomized as yes, for a positive answer
to use of any one of them or no, if none of them has ever been used. Participants were also asked: have you ever had rehabilitation?
We included the response on a dichotomized level as yes or no (Table 1a). Those who responded yes to the question (do you have health
insurance?) were compared to those who said no for analysis in the multivariate model.
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2.7. Statistical methods

3.2. Unadjusted results

We downloaded data using SPSS and analyzed with Stata/MP
11.2 software package. We compared basic demographic and
clinical variables by cigarette smoking and marijuana use status.
Unadjusted and multivariate logistic regression analysis was
used to determine the association between cigarette smoking and
marijuana use with metabolic syndrome and its compo- nents.
Emphasis was placed on the duration (years) of smoking
cigarette and/or marijuana use. We applied the appropriate
weights in both our bivariate and multivariate analysis. The
model, adjusted for age, gender, education, poverty to income
ratio, participation in at least moderate physical activity, weekly
alcohol use, other illicit drug use (methamphetamine, heroin or
cocaine), having had rehabilitation, marital status and having
health insurance. We considered p-value below 0.05 as statistically signiﬁcant.

Unadjusted logistic regression shows that current smokers have
an odds ratio of 1.43 (95% CI: 1.13, 1.81) for having high blood
pressure, and 1.61 (95% CI: 1.01, 2.55) for having high triglyceride
levels than nonsmokers (Table 2). The unadjusted model for
marijuana use shows that each year of using marijuana is
associated with an odds ratio of 1.02 (1.00, 1.04) of having
metabolic syndrome. A signiﬁcant increased odds with each year of
cigarette smoking is observed for hypertension (OR: 1.03, 95% CI:
1.02, 1.03), hypertriglyceridemia (OR: 1.03, 95% CI: 1.02, 1.04) and
hyperglycemia (OR: 1.02, 95% CI: 1.00, 1.03). Each year increase in
marijuana use is also associated with a signiﬁcant increase in odds
for hypertension (OR: 1.01, 95% CI: 1.00, 1.02), hypertriglyceridemia (OR: 1.01, 95% CI: 1.00, 1.03) and hyperglycemia (OR: 1.02,
95% CI: 1.00, 1.03) (Table 2).
3.3. Adjusted results

3. Results

Multivariate logistic regression analysis adjusted for age,
gender, education, participation in at least moderate physical
activity, weekly alcohol use, income to poverty ratio, having health
insurance, marital status, other illicit drug use and having had
rehabilitation. Controlling for these factors, the odds ratio for each
year increase of using marijuana is 1.05 (95% CI: 1.01, 1.09) for
metabolic syndrome and 1.04 (95% CI: 1.01, 1.07) for hypertension
(Table 3a). In this same model, each year of smoking cigarettes is
associated with an odds ratio of 1.03 (95% CI: 1.00, 1.06) for
hypertension as well as 1.03 (95% CI: 1.01, 1.05) for hyperglycemia.
By marijuana use status, the results show signiﬁcant reduced odds
for MetS (OR 0.23; 95% CI: 0.06, 0.90), hypertension (OR 0.31; 95%
CI: 0.13, 0.70) and hypertriglyceridemia (OR 0.70; 95% CI 0.50, 0.99)
among regular marijuana users compared to non-users (Table 3a).
We did not ﬁnd signiﬁcant associations between smoking
cigarettes or marijuana use and low levels of HDL in this analysis.
Table 3b shows results for multivariate analysis separately among
cigarette smokers and separately for marijuana users.

3.1. Demographic and clinical characteristics
The total sample consisted of 3051 participants, 50.9% men and
49.1% women with an average age of 38.7 ± 11.7 years (average
weighted age was 39.6 ± 0.7, not shown in table) ranging from 20 to
59 years. Overall 59.3% of study participants were nonsmokers,
24.0% were current smokers and 16.7% were former smokers.
Approximately 47.0% of study participants were regular marijuana
users, 26.2% have never used marijuana while 27.0% were nonregular users of marijuana. Among those who were regular
marijuana users, 47.7% were current cigarette smokers as well,
25.7% were past cigarette smokers and 26.6% have no history of
tobacco use (not shown in table). The demographic distribution by
cigarette smoking or marijuana use status is shown in Table 1a. The
prevalence and weighted averages of the components of metabolic
syndrome are shown in Table 1b. Apart from fasting glucose, there
are signiﬁcant differences in these factors by cigarette smoking
status. Stratifying by marijuana use status shows signiﬁcant
differences for systolic blood pressure and waist circumference.
The prevalence of metabolic syndrome among all the study
participants is 23.5%.

4. Discussion
Research supports the science that the endocannabinoid
system as well as chronic smoking of cannabis is associated with
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Table 2
Unadjusted analysis of having metabolic syndrome or risky levels of components of metabolic
Variable

Cigarette, odds ratio (95% CI)

Marijuana, odds ratio
(95% CI)

A. Years of smoking
Metabolic

syndrome.

B. Smoking status

C. Years of use

Current
Past

1.51 (0.80, 2.87)
1.64 (0.97, 2.79)

1.02 (1.00, 1.04)

Regular
Non-regular

1.01 (0.56, 1.84)
0.87 (0.67, 1.14)

1.01 (0.09, 1.01)

Current
Past

0.92 (0.66, 1.28)
1.11 (0.74, 1.66)

1.01 (0.99, 1.02)

Regular
Non-regular

0.81 (0.59, 1.11)
0.89 (0.70, 1.11)

1.03 (1.02, 1.03)

Current
Past

1.43 (1.13, 1.81)
1.53 (0.94, 2.50)

1.01 (1.00, 1.02)

Regular
Non-regular

1.82 (0.57, 1.19)
0.94 (0.72, 1.23)

1.02 (1.00, 1.03)

Current
Past

1.46 (0.86, 2.48)
1.22 (0.69, 2.16)

1.01 (1.00, 1.03)

Regular
Non-regular

1.10 (0.52, 1.34)
1.01 (0.56, 1.41)

Current

1.61 (1.01, 2.55)

1.02 (1.00, 1.03)

Regular

1.21 (0.71, 2.07)

Past

1.40 (0.93, 2.11)

Non-regular

1.21 (0.80, 1.82)

Current
Past

1.28 (0.93, 1.75)
0.95 (0.63, 1.43)

Regular
Non-regular

0.97 (0.65, 1.45)
0.88 (0.61, 1.27)

syndrome
1.00 (0.99, 1.02)

D. Use status

Abdominal obesity

Hypertension

Hyperglycemia

Hypertriglyceridemia
1.03 (1.02, 1.04)
Low HDL cholesterolemia
1.00 (0.09, 1.00)

1.01 (0.99, 1.02)

A, The relationship between each year increase in cigarette smoking with the listed variables; B, The relationship between current smoker or past smoker compared to nonsmokers and the listed variables; C, The relationship between each year increase in marijuana use and the listed variables; D, The relationship between regular marijuana
users or non-regular marijuana users and the listed variables.
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Table 3a
Multivariate analysis of metabolic syndrome/components with years of cigarette and MJ use controlling for other risk factors.

1

Marijuana use
Cigarette smoking1
Regular MJ user
Cigarette smoker
MJ Quantity2
Cigarette Quantity2
Age 25+
Males
Whites
Education
PIR3
Insured
Married
Moderate PA4
Alcohol Intake5
Other drug use
Rehabilitation

Metabolic SYN

AO

HPT

HYPGLY

HYPTRIG

Low HDLC

1.05 (1.01, 1.09)
1.00 (0.09, 1.00)
0.23 (0.06, 0.90)
1.24 (0.96, 1.59)
1.25 (0.80, 1.95)
0.99 (0.90, 1.02)
2.70 (1.60, 4.54)
0.94 (0.58, 1.50)
1.08 (0.67, 1.73)
0.83 (0.72, 0.94)
0.87 (0.76, 1.01)
1.33 (0.76, 2.35)
1.50 (0.87, 2.57)
0.82 (0.46, 1.46)
1.10 (0.61, 1.98)
1.48 (0.86, 2.58)
0.83 (0.37, 1.86)

1.03 (0.99, 1.07)
1.00 (0.09, 1.01)
0.45 (0.14, 1.43)
0.93 (0.74, 1.17)
1.05 (0.77, 1.41)
0.98 (0.96, 1.00)
2.75 (1.10, 6.84)
0.28 (0.19, 0.42)
1.42 (0.99, 2.04)
0.82 (0.67, 1.00)
0.91 (0.84, 0.99)
1.07 (0.73, 1.58)
1.12 (0.74, 1.69)
0.94 (0.65, 1.36)
1.47 (0.95, 2.25)
1.16 (0.52, 2.58)
0.67 (0.36, 1.25)

1.04 (1.01, 1.07)
1.03 (1.00, 1.06)
0.31 (0.13, 0.70)
0.81 (0.49, 1.36)
0.98 (0.75, 1.28)
1.00 (0.97, 1.02)
3.95 (2.06, 7.57)
1.29 (0.87, 1.91)
1.08 (0.81, 1.45)
0.93 (0.79, 1.11)
0.92 (0.82, 1.03)
1.77 (1.02, 3.07)
0.99 (0.60, 1.64)
1.05 (0.84, 1.32)
1.82 (1.07, 3.08)
0.63 (0.40, 0.99)
1.04 (0.54, 2.00)

1.01 (0.97, 1.05)
1.03 (1.01, 1.05)
0.61 (0.18, 2.08)
0.74 (0.52, 1.04)
1.17 (0.82, 1.67)
0.99 (0.97, 1.02)
2.68 (1.45, 4.97)
1.81 (1.20, 2.72)
0.98 (0.72, 1.33)
0.89 (0.76, 1.04)
1.01 (0.90, 1.14)
1.22 (0.91, 1.63)
1.03 (0.71, 1.47)
0.75 (0.54, 1.04)
0.83 (0.44, 1.57)
0.88 (0.61, 1.26)
0.94 (0.44, 2.01)

1.02 (0.99, 1.04)
0.99 (0.18, 5.45)
0.70 (0.50, 0.99)
0.68 (0.33, 1.40)
1.03 (1.01, 1.05)
0.99 (0.96, 1.02)
2.05 (1.01, 4.15)
1.60 (1.06, 2.41)
1.16 (0.82, 1.65)
1.06 (0.88, 1.28)
0.95 (0.85, 1.06)
1.00 (0.60, 1.66)
1.33 (0.89, 1.98)
0.94 (0.61, 1.47)
1.45 (0.90, 2.34)
1.02 (0.99, 1.04)
0.99 (0.18, 5.45)

1.03 (0.99, 1.06)
1.00 (0.09, 1.00)
0.53 (0.19, 1.44)
0.97 (0.77, 1.23)
1.07 (0.80, 1.43)
1.01 (0.98, 1.03)
1.41 (0.73, 2.73)
0.84 (0.55, 1.26)
1.07 (0.70, 1.62)
0.95 (0.76, 1.19)
0.91 (0.78, 1.05)
1.40 (0.93, 2.10)
1.31 (1.01, 1.70)
0.82 (0.59, 1.14)
1.06 (0.76, 1.49)
1.21 (0.78, 1.87)
0.67 (0.36, 1.27)

1

Each year increase in use/smoking; 2Number of joints/cigarettes; 3Family Income-to-Poverty Ratio; 4At least moderate physical activity (recreational); 5Weekly. Bold values

indicate signiﬁcance at alpha ::; 0.05. MJ, marijuana; SYN, syndrome; AO, abdominal obesity; HPT, hypertension; HYPGLY, hyperglycemia; HYPTRIG, hypertriglyceridemia;
HDL, high density lipoprotein cholesterol.
All odds ratios with 95% CI starting from 1 and not in bold are due to rounding and have p-values above 0.05.

Table 3b
Adjusted analysis for metabolic syndrome and components separately for cigarette smoking and marijuana use.
Variable

Metabolic syndrome
Abdominal obesity
Hypertension
Hyperglycemia
Hypertriglyceridemia
Low HDL cholesterolemia

Cigarette use
Odds ratio (95% CI)

Marijuana use
Odds ratio (95% CI)

(A) Years of smoking

(B) Current

(A) Years of use

(B) Regular user

1.00 (0.09, 1.00)
1.01 (0.99, 1.03)
1.04 (1.01, 1.07)
1.03 (1.01, 1.05)
1.04 (1.02, 1.06)
1.00 (0.09, 1.00)

1.17 (0.90,1.52)
0.84 (0.55, 1.29)
0.67 (0.40, 1.11)
0.71 (0.43, 1.08)
0.62 (0.46, 0.85)
0.96 (0.77, 1.20)

1.05 (1.01, 1.09)
1.03 (0.99, 1.07)
1.05 (1.02, 1.09)
1.02 (0.98, 1.06)
1.03 (1.01, 1.06)
1.02 (0.99, 1.05)

0.25 (0.06, 1.02)
0.42 (0.13, 1.36)
0.26 (0.10, 0.67)
0.50 (0.13, 1.89)
0.76 (0.15, 3.97)
0.54 (0.18, 1.55)

CI, conﬁdence interval; adjusted analysis is based on the model in Table 3a and shows only the odds ratios for respective dependent variables in the table for: Each year
increase in smoking cigarette. Current smoker compared to non-smoker or former smoker. Each year increase in marijuana use. Regular marijuana user compared to nonregular or non-user.

metabolic irregularities including abdominal obesity and insulin
resistance [18–21]. In our research, basic examination characteristics show that, among the study participants, regular marijuana

cigarette also increases the odds of having hypertension by 3.0% as
well as hyperglycemia by 3.0%. Separate models that concentrated
on smoking alone or marijuana use alone yielded results that were
similar (Table 3b).
With respect to ﬁndings in existing research, marijuana users
and cigarette smokers may be showing better metabolic proﬁles by
status. However, the relationship between duration of use in this
study draws our attention to a possible long-term adverse effect.
For example in our model, marijuana users are 77.0% less likely to
have metabolic syndrome, 69.0% less likely to have hypertension
and 30.0% less likely have hypertriglyceridemia compared to nonusers, however considering years of use, the relationship shows a
higher odds for MetS and some of its components. This ﬁnding
suggests that, the duration of marijuana use or smoking is an
important factor in assessing metabolic health and that with
prolonged years of use, the effects on metabolic health may be
unfavorable. It is worth noting that we considered the effect of age
transition on metabolic factor as well.
Although the harmful effect of cigarette smoking on cardiovascular health is well known [24–27], the effect on some metabolic
health factors is not deﬁnite [11,12] neither is that for marijuana
use. Universal ﬁndings on this effect can have important
implications for public health and chronic disease management.
With respect to factors of metabolic syndrome, some research
show that marijuana use is associated with lower insulin levels
[28] as well as less prevalence of diabetes among users and that
it needs to be investigated in the management of diabetes [29].
Marijuana (cannabis) exerts its effect on the endocannabinoid

users had an average waist circumference higher (98.5 ± 1.4) than
that for the general participants (97.8 ± 0.8). Research also shows
that cigarette smoking causes inﬂammation which is a precursor for
metabolic syndrome. Smoking increases the production of procytokines, reduces levels of anti-inﬂammatory cytokines [22] and
increases pathologic levels of inﬂammation-sensitive proteins like
alpa1-antitripson, ﬁbrinogen, etc. [23]. In our study, by status,
unadjusted analysis showed no signiﬁcant increase in odds for MetS
among those who smoke cigarettes or those who use marijuana when
compared to those who do not (Table 2). Current cigarette smokers,
however, had 43.0% increase in odds for high blood pressure and
61.0% increase for high serum triglycerides compared to nonsmokers.
The relationship between metabolic syndrome and marijuana
use or cigarette smoking appears to be associated with the years of
use/smoking. Our results show signiﬁcant associations between
years of marijuana use or cigarette smoking and metabolic
syndrome as well as some of its components. This ﬁnding needs
further investigation with respect to the duration of use or cutoff
point that is likely to put one at the most disadvantage for
metabolic abnormalities. In multivariate analysis, even though by
cigarette smoking or marijuana use status the relationship may
seem protective, we ﬁnd otherwise by duration of use. Each year of
marijuana use was associated with a signiﬁcant 5.0% increase in
odds of having metabolic syndrome and 4.0% increase in odds of
having hypertension (Table 3a). Each year increase in smoking
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NHANES has data on cotinine as a marker for cigarette smoking,
laboratory results on THC is yet to be available.

system by acting on cannabinoid receptors. Cannabinoid receptors
are stimulated by endocannabinoids that are endogenous ligands.
Both cannabinoid receptor 1 (CB1) and receptor 2 (CB2) are
involved in regulation of energy balance, appetite, insulin
sensitivity and lipid metabolism [15,21,30,31]. Research on
marijuana and metabolic syndrome is still geminating and without
deﬁnite results. Research conducted by Penner et al. [28] based on
a multiple linear regression model concluded that marijuana use
was associated with lower levels of fasting insulin and lower waist
circumference, with the inference that marijuana users may have a
good glycemic proﬁle. A cross-sectional study by Muniyappa et al.
[20] on the chronic effect of marijuana smoking on metabolic
syndrome showed that those who smoke marijuana had a higher
percent abdominal visceral fat, lower plasma HDL cholesterol,
lower adipocyte insulin resistance index and lower percent free
fatty acid (FFA) suppression during an oral glucose tolerance test
(OGTT). A study by Thompson and Hay [32,33] questions the use of
a linear regression in estimating this association and consequently
recommend other analysis and models that consider factors
endogenous to marijuana use. In our study we used logistic
regression analysis and controlled for some factors endogenous to
recreational substance like other drug use, rehabilitation, marriage, alcohol use, health insurance and income to poverty ratio.
Available literature on smoking also shows that smoking has
nonlinear relationships with factors of metabolic syndrome
especially among moderate smokers, but heavy smoking of
20 cigarettes or more daily leads to adverse levels of metabolic
factors [11]. In this exploratory study we controlled for increasing
quantity of cigarette or marijuana used. A near signiﬁcant
reduction in abdominal obesity was found with increased quantity
smoked. This relationship between smoking and weight or
abdominal obesity has been demonstrated in some studies with
varying results as well [34]. Even though reported bias may play a
role, it is of interest to examine the effect of quantity of marijuana
smoked in subsequent models because there is a biological basis
between smoking and weight. Whilst considering years of
marijuana use or cigarette smoking, the use of biological markers
for smoking and marijuana use with cut offs might also be of
importance in future studies to assess the causal effects of
recreational substance use on metabolic health using longitudinal
data.

5. Conclusion
Increased years of marijuana use or cigarette smoking are
associated with unhealthy levels of the components of metabolic
syndrome among adults in the US. With the inclination for
recreational marijuana use, this relationship may be considered
critically to avert future metabolic complications. The duration of
marijuana use or cigarette smoking is potentially an important
factor in assessing metabolic health. With prolonged years of use,
the effects on metabolic health might be unfavorable. We also
found that marijuana use like cigarette smoking is also associated
with hypertension. Our research seeks to add to the geminating
interest in research on metabolic syndrome and marijuana use and
cigarette smoking as an illuminating pathway to addressing
recreational substance use and factors associated with cardiometabolic diseases, a major cause of morbidity and mortality.
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[21] Blüher M, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006;55(11):
3053–60.
[22] Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity,
inﬂammation and autoimmunity. J Autoimmunity 2010;34(3):J258–65.
[23] Lind P, et al. Risk of myocardial infarction and stroke in smokers is related to
plasma levels of inﬂammation-sensitive proteins. Arterioscler Thromb Vasc
Biol 2004;24(3):577–82.
[24] Lakier JB. Smoking and cardiovascular disease. Am J
Med 1992;93(1):S8–12.
[25] Villablanca AC, McDonald JM, Rutledge JC. Smoking and cardiovascular disease. Clin Chest Med 2000;21(1):159–72.
[26] Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am College Cardiol 2004;43(10):1731–7.
[27] Burns DM. Epidemiology of smoking-induced cardiovascular disease. Prog
Cardiovasc Dis 2003;46(1):11–29.

[29]

[30]
[31]
[32]

[33]
[34]

[28]

44

S95

Penner EA, Buettner H, Mittleman MA. The impact of marijuana use on glucose,
insulin, and insulin resistance among US adults. Am J Med 2013;126(7):583–9.
Rajavashisth TB, et al. Decreased prevalence of diabetes in marijuana users:
cross-sectional data from the National Health and Nutrition Examination
Survey (NHANES) III. BMJ Open 2012;2(1):e000494.
Engeli S, Jordan J. The endocannabinoid system: body weight and metabolic
regulation. Clin Cornerstone 2006;8:S24–35.
Bellocchio L, et al. Cannabinoid receptors as therapeutic targets for obesity and
metabolic diseases. Curr Opin Pharmacol 2006;6(6):586–91.
Thompson CA, Hay JW. Estimating the association between metabolic risk
factors and marijuana use in U.S. adults using data from the continuous
National Health and Nutrition Examination Survey. Ann Epidemiol
2015;25(7):486–91.
Thompson CA, Hay JW. Marijuana use in models for health outcomes. Am J Med
2015;128(3):pe23.
Koh-Banerjee P, et al. Prospective study of the association of changes in
dietary intake, physical activity, alcohol consumption, and smoking with 9y gain in waist circumference among 16 587 US men. Am J Clin Nutr
2003;78(4):719–27.

CHAPTER 3
Journal of Addiction Research &
Therapy
Research Article

Yankey et al., J Addict Res Ther 2017, S11:017
DOI: 10.4172/2155-6105.1000S11-017

OMICS International

Relationship between Years of Marijuana Use and the Four Main Diagnostic Criteria for Metabolic
Syndrome among United States Adults
Barbara A Yankey1*, Richard Rothenberg2, Sheryl Strasser3, Kim Ramsey-White4 and Ike S Okosun1
1Georgia

State University, School of Public Health, Division of Epidemiology and Biostatistics, 140 Decatur Street NE, Suite 848, Atlanta, GA 30303, USA

2Georgia

State University, School of Public Health, Division of Research and Faculty Development, Tobacco Center of Regulatory Science, 140 Decatur Street NE.,
Suite 857 Urban Life Bldg, Atlanta, GA 30303, USA
3Georgia

State University, School of Public Health, Division of Health Promotion and Behavior, 140 Decatur Street NE, Suite 848, Atlanta, GA 30303, USA

4Georgia

State University, School of Public Health, Division of Research Training/Education Core (RTE), Center for Excellence in Health Disparities, 1 Park Place NE,
Suite 709, Atlanta, GA 30303, USA
*

Corresponding author: Barbara A. Yankey, Division of Epidemiology and Biostatistics, Georgia State University School of Public Health, USA, Tel: 404-413-1138; Email: byankey1@student.gsu.edu

Received date: January 09, 2017; Accepted date: February 12, 2017; Published date: February 19, 2017
Copyright: © 2017 Yankey BA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract
Objective: Research on marijuana use suggests a protective effect on metabolic syndrome. National Cholesterol
Education Program, Adult Treatment Panel III, World Health Organization, European Group for the study of Insulin
Resistance and International Diabetes Federation have different criteria for metabolic syndrome. Definitions of both
marijuana use and criteria for metabolic syndrome may influence the observed effects. We examine the relationship
of years of marijuana use with the four common definitions of metabolic syndrome.
Method: This is a cross-sectional study of 3051 adults aged ≥ 20 years who participated in the National Health and
Nutrition Examination Survey 2011-2012. Only participants who responded to the question, “Have you ever even
once used marijuana or hashish?” were enrolled. Using multivariate logistic regression, we estimated odds ratios for
metabolic syndrome with each year of marijuana use.
Results: Adjusted odds ratios (AOR) for having metabolic syndrome with each increase in year of marijuana use
was 1.05 (95% CI: 1.02, 1.08) using National Cholesterol Education Program Adult Treatment Panel III (ATP III)
criteria. Respective AOR using International Diabetes Federation (IDF) was 1.08 (95% CI: 1.04, 1.13) and 1.05 (95%
CI: 1.04, 1.13) using World Health Organization (WHO) or European Group for the study of Insulin Resistance (EGIR)
criteria. Using ATP III or IDF criteria, the adjusted odds ratio of having hypertension (AOR Hyp) for each year of
marijuana use was 1.07 (95% CI: 1.03, 1.12). Using WHO criteria, AOR Hyp was 1.05 (95% CI: 1.01, 1.09) and
1.08 (95% CI: 1.03, 1.12) using EGIR. All the applicable criteria show increased odds for abdominal obesity: AOR
1.06 (95% CI: 1.00, 1.11) (ATP III), 1.09 (95% CI: 1.05, 1.14) (EGIR) or 1.07 (95% CI: 1.01, 1.13) (IDF). Adjusted odds
ratio for having high oral glucose tolerance test levels was 1.12 (95% CI: 1.07, 1.18) using WHO and EGIR criteria.
Conclusion: Irrespective of the criteria for metabolic syndrome, each year of marijuana use showed increased
odds of having metabolic syndrome, hypertension or high oral glucose tolerance test levels. This increased odd is in
contrast to most findings in literature. The small, yet consistent increase in odds for hypertension was slightly higher
than that observed with cigarette smoking. Recreational marijuana use may be detrimental to cardiovascular health.
A standardized definition of marijuana use will be relevant for further investigation.

effect of tobacco/cigarette on cardiovascular health is established, that
of marijuana is unknown.

Keywords: Cannabis; Cardiovascular disease; Cigarette; Marijuana;
Metabolic syndrome; Tobacco

Metabolic syndrome (MetS) is a constellation of cardiovascular risk
factors and is a condition associated with detrimental cardiovascular
prognosis. Because cardiovascular disease (CVD) is a leading cause of
mortality worldwide [2], the prevalence of metabolic syndrome may be
an important determinant of the health status of a nation. The prevalence
of metabolic syndrome generally increases with age. During the period
2003 to 2012, metabolic syndrome prevalence in the United States (US)
was about 18.0% among adults aged 20-39 years, 35.0% among adults
aged 40-59 years and 46.7% among adults aged 60 years and above [3].
In 2012, an estimated 31.0% of all global deaths were due to CVDs [4].
Studies on tobacco and marijuana are inconclusive

Introduction
Marijuana is a psychoactive substance that induces relaxation and
euphoria. Marijuana is classified as a schedule 1 drug by the drug
enforcement administration (DEA) and is an illicit compound under
federal law. However, by the end of election 2016, 28 states had
legalized medical marijuana. Eight states and Washington DC also
permit adult recreational marijuana use. Support for legalization of
marijuana is on ascendancy [1]. Like cigarette, the main route of
administration of marijuana is smoking and whereas the detrimental
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marijuana use and criteria for metabolic syndrome may influence the
observed effects. We examine the relationship of years of marijuana use
with the four common definitions of metabolic syndrome. Our
hypothesis is that the definition used for metabolic syndrome may
change the estimates of the associations between marijuana use and
metabolic syndrome.

on their associations with metabolic syndrome and its components [2,5].
Metabolic syndrome has varying criteria. National Cholesterol Education
Program, Adult Treatment Panel III (ATP), World Health Organization
(WHO), European Group for the study of Insulin Resistance (EGIR) and
International Diabetes Federation (IDF) have different criteria for
metabolic syndrome. Definitions of both

Variable

Sample Size (%)

Race
NHW

NHB

MA

OHISP

ASIANS

ORACE

Marijuana Use***
Never

1427 (46.80)

33.78

42.86

61.09

58.72

73.30

33.56

Non-regular

824 (27.03)

33.51

25.66

23.10

21.71

18.74

28.70

Regular

798 (26.17)

32.7

31.48

15.81

19.57

7.60

40.74

Never

1807 (59.25)

48.43

63.26

64.13

62.63

74.94

55.56

Past

510 (16.72)

20.49

11.74

19.15

19.22

13.11

14.81

Current

733 (24.03)

31.09

25.00

16.72

18.15

11.94

29.63

Male

1552 (50.87)

52.02

46.66

54.71

48.04

53.40

55.56

Female

1499 (49.13)

47.98

53.34

45.29

51.96

46.60

44.44

Married

1371 (44.94)

49.15

31.65

52.28

41.28

56.91

38.89

Other

1680 (55.06)

50.85

68.35

47.72

58.72

43.09

61.11

USA

2154 (70.65)

95.06

89.91

41.77

26.79

19.67

80.56

Other Countries

895 (29.35)

4.94

10.09

58.23

73.21

80.33

19.44

≤ High School Graduate

1172 (38.41)

33.42

38.97

69.6

52.31

19.44

29.63

≥ Some College

1879 (61.59)

68.58

61.03

30.6

47.69

80.56

70.37

20-25

543 (17.80)

15.09

20.43

15.50

17.08

19.44

28.70

Above 25

2508 (82.20)

84.91

79.57

84.50

82.92

80.56

71.30

<1.00

753 (26.39)

24.91

31.12

30.95

30.15

15.56

27.18

1.00 to 2.99

1048 (36.73)

36.02

36.93

42.52

43.13

29.16

38.83

3.00 to 4.99

555 (19.45)

19.26

19.09

18.03

17.94

24.04

14.56

>5.00

497 (17.42)

19.81

12.86

8.50

8.78

31.20

19.42

No

2504 (82.23)

74.41

87.01

80.49

87.14

94.6

71.30

Yes

541 (17.77)

25.59

12.99

19.51

12.86

5.40

28.70

Cigarette smoking***

Gender*

Marital

Status***

Country of

Birth***

Education***

Age groups (Years)**

PIR***

Other Drug Use***
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Ever had rehabilitation***
No

2877 (94.30)

92.54

92.18

97.57

96.44

99.30

92.59

Yes

174 (5.70)

7.46

7.82

2.43

3.56

0.70

7.41

Table 1a: Proportions of recreational substance use and demographic characteristics of participants stratified by race, Percentages are column
percentages. Chi square tests (*P<0.05, **P<0.01, ***P<0.001) show significant differences among the various racial ethnic groups. MA: Mexican
Americans; NHW: Non-Hispanic Whites; NHB: Non-Hispanic Blacks; OHISP: Other Hispanics; ORACE: Other Race or Multiracial; PIR: Family
Income to Poverty Ratio.

Literature Review

Dependent variable: Our main dependent variable was MetS. We
used the four most widely accepted definitions of MetS. In accordance
with 2005 modification of ATP III criteria for Mets, we classified
participants as having MetS if they had a co-occurrence of three or more
of the following: Hypertension-an average blood pressure
>130/85 mm Hg or use of medication for hypertension; Hyperglycemiadefined as fasting plasma glucose (FBG) ≥ 100 mg/dl or use of
medication for diabetes; Abdominal obesity or high waist
circumference-defined as females with waist circumference >88.0 cm
and males with waist circumference >102.0 cm; Low HDL
cholesterolemia-defined as plasma HDL-C levels <50 mg/dl for females
and <40 mg/dl for males or use of medications for
hypercholesterolemia; and Hypertriglyceridemia-defined as plasma
triglycerides ≥ 150 mg/dl or use of medication for
hypercholesterolemia. Details of laboratory and clinical procedures are
described in the NHANES manual.

Metabolic syndrome is a co-occurrence of hypertension,
hyperlipidemia, hyperglycemia and visceral obesity. Metabolic
syndrome is associated with cardiometabolic pathology [6]. There is no
unified definition [7,8] for MetS, however, the definition by the National
Cholesterol Education Program, Adult Treatment Panel III (ATP III) is
widely adopted because of its clinical applicability [8]. In accordance
with ATP III, MetS is a co-occurrence of any three of the following:
Hypertension, hyperglycemia, abdominal obesity, reduced high density
lipoprotein cholesterol (HDL-C) or hypertriglyceridemia. By WHO
standard, MetS is a diagnosis of diabetes or increased two hour oral
glucose tolerance test (OGTT) or fasting insulin levels plus any two or
more of the following: hypertension, obesity, high plasma triglycerides,
low plasma HDL-C or albumin creatinine ratio ≥ 30. By EGIR criteria,
MetS consists of fasting insulin level above 75th percentile of cohorts,
and two or more of the following: hypertension, abdominal obesity,
hypertriglyceridemia or low HDL-C. The IDF criteria require increases
in ethnicity-specific waist circumference and any two or more of the
following: hypertension, hypertriglyceridemia, low plasma HDL-C and
high fasting plasma glucose or diagnosis of diabetes [8].

By WHO criteria, participants who said they had been diagnosed
with diabetes by a doctor or were using medications for diabetes, or had
a two hour oral glucose tolerance test (OGTT) result 140 mg/dl, or
fasting insulin levels >25.2 µIU/ml and had any two or more of the
following: average blood pressure 140/90 mmHg; body mass index >30
kg/m2; plasma triglycerides 150 mg/dl; plasma HDL-C levels <39 mg/dl
(for females) or <35 mg/dl (for males); and albumin creatinine ratio 30.

Results from research on marijuana use and MetS suggest a
protective effect of marijuana use for MetS and some of its components
[5,9]. Although some therapeutic effects of extracts of cannabis
(marijuana plant) can be anticipated [10], these benefits may not apply
to recreational use of marijuana. In the US, tobacco and marijuana are
the most common substances of abuse after alcohol [11]. Statistics from
the 2014 National Survey of Drug Use and Health, under the Substance
Abuse and Mental Health Services Administration, show that among
US adults aged 18-25 years, the lifetime prevalence of alcohol, cigarette
and marijuana use were 83.4%, 56.1% and 52.6%, respectively whilst
among US adults aged 26 years and above, lifetime prevalence were
88.3%, 67.5% and 46.1%, respectively [12]. With a likely increase in
marijuana use arising from legalization of marijuana, it is important to
assess the relationship with determinants of cardiovascular disease.

By EGIR criteria, participants whose fasting insulin level fell above
75th percentile of this study group and had two or more of the following:
average blood pressure ≥ 140/90 mm Hg or use of medications for
hypertension; waist circumference ≥ 94 cm if male or
≥ 80 cm if female; plasma triglyceride ≥ 150 mg/dl; HDL-C ≥ 39 mg/dl.
By IDF criteria, ethnicity-specific waist circumference being ≥ 94 cm
(for black males) or ≥ 80 cm (for black females); ≥ 102 cm (for white
males) or ≥ 88 cm (for white female), and ≥ 94 cm or ≥ 80 cm for males
and females respectively who were Asians/Mexican American/
Multiracial and had any two or more of the following: average blood
pressure>130/85 mmHg or on medication for hypertension; plasma
triglyceride ≥ 150 mg/dl or on anti-cholesterol medications; plasma
HDL-C ≤ 50 mg/dl (for females) or ≤ 40 mg/dl (for males); and fasting
plasma glucose ≥ 100 mg/dl diagnosis of diabetes by a doctor.

Method
Data and variables

Main independent variable: According to the questions in NHANES,
participants who had never used marijuana/hashish were categorized as
never marijuana users. Those who said they had used marijuana/hashish
but not up to once a month for more than a year were classified as nonregular marijuana users and those who had used marijuana or hashish at
least once a month for more than a year were classified as regular
marijuana users.

This is a cross-sectional study of adults aged 20 years and above who
participated in the National Health and Nutrition Examination Survey
(NHANES) 2011-2012. Only participants who responded to the
question, “Have you ever even once used marijuana or hashish?” were
enrolled.

Volume S11 • Issue 017 • S11-017

J Addict Res Ther, an open access journal
ISSN:2155-6105

41

Citation: Yankey BA, Rothenberg R, Strasser S, White KR, Okosun IS (2017) Relationship between Years of Marijuana Use and the Four Main
Diagnostic Criteria for Metabolic Syndrome among United States Adults. J Addict Res Ther S11: 017. doi: 10.4172/2155-6105.1000S11-

017

We estimated years of marijuana use by subtracting each participant’s
age at regular marijuana use from their current age. For participants who
were non-regular users of marijuana, we assigned zero years of
marijuana use. Our multivariate logistic analysis included

only marijuana users (regular users or non-regular-users) to enable us
assess the effect among those who had ever used marijuana and avoid
placing non-regular marijuana users and never marijuana users on the
same level.
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Variable

Diagnostic Criteria
WHO

EGIR

ATP III

IDF

Overall

9.21

8.55

23.17

23.37

Regular marijuana

8.40

8.40

20.93

21.3

Current cigarette smoker

9.41

9.14

24.83

24.69

NHW

9.43

9.97

24.71

22.01

NHB

9.21

8.07

25.73

25.98

MA

14.89

10.33

24.62

28.27

OHISP

7.83

5.69

21.71

25.27

ASIANS

5.39

6.79

15.46

18.03

ORACE

8.33

6.48

18.52

19.44

Overall

10.56

23.89

31.69

31.69

Overall

19.04

8.19

21.86

23.43

Overall

3.61

61.42

-

-

Overall

5.97

5.97

-

-

Overall

11.67

11.67

18.49

18.49

Overall

10.49

15.34

34.81

34.81

Overall

-

69.59

49.80

64.15

NHW

-

-

-

50.07

NHB

-

-

-

69.59

ASIANS/MA/OHISP/OR

-

-

-

74.57

Overall

35.59

-

-

-

Overall

13.27

-

-

-

Metabolic Syndrome

BY SUBSTANCE USE (Yes)

BY RACE (Yes)

Hypertension

Hyperglycemia

Hyperinsulinemia

High OGTT Level

Hypertriglyceridemia

Low HDL-C

High WC

BMI >30 kg/m

2

High Albumin/Creatinine Ratio

Table 1b: Prevalence in Percentages of Metabolic Syndrome Diagnosis and its Components by the Different Criteria.
NHW: Non-Hispanic Whites; NHB: Non-Hispanic Blacks; MA: Mexican Americans; OHISP: Other Hispanics; ORACE: Other Race or
Multiracial; OGTT: Oral Glucose Tolerance Test; HDL-C: High Density Lipoprotein Cholesterol; WC: Waist Circumference; BMI: Body Mass
Index.
Other independent variables: We included cigarette smoking. We
classified participants who reported they have smoked at least 100
cigarettes their entire life and still smoke every day or some days as
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current cigarette smokers. Those who have smoked at least 100 cigarettes
but do not currently smoke at all were past smokers. Those who had never
smoked cigarettes were non-smokers. Non-smokers or past smokers were
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assigned zero years of smoking cigarettes. Years of smoking for current 20.9% (ATP III) whilst the proportion of MetS among cigarette smokers
smokers was estimated by subtracting reported initial age at regular was 26.0% (IDF) and 25.7% (ATP III). By race/ethnicity, ATP III
smoking from their current age.
classifies the 25.7% of non-Hispanic Blacks as having MetS. All other
criteria predominantly classify Mexican Americans (MA) as having
MetS (28.3%-IDF, 14.9%-WHO and 10.3%-EGIR).
In the multivariate model, we controlled for age of participant,
Hypertension, hypertriglyceridemia, and Low HDL-C are more
gender, race, education, marital status, poverty to income ratio (PIR),
participation in at least moderate physical activity, days of alcohol use prevalent (31.7%, 18.5%, 34.8%, respectively) using ATP III and IDF
in a week, other recreational substance use (methamphetamine, heroin criteria. The prevalence of hyperglycemia is 21.9% using ATP III and
or cocaine) and participation in rehabilitation. Details of the 23.4% using IDF. Disparities in prevalence for other components are
measurement of these control variables are described in NHANES shown in Table 1b.
manual.

Statistical analysis
We used Stata/IC 14.0 software package for analysis. We estimated
the proportions of demographic and clinical variables by race to have
an appreciation of the differences. Disparities in socioeconomic factors
as well as race/ethnicity have been described as important factors for
metabolic abnormalities as well as recreational substance use [13,14].
Using logistic regression analysis, we estimated unadjusted and adjusted
odds ratios for MetS among regular and non-regular marijuana users.
In all analyses we applied the appropriate weights for the NHANES
multi-stage survey design and used a two-tailed significance level of
α=0.05
(http://www.cdc.gov/nchs/data/nhanes/nhanes3/
cdrom/NCHS/MANUALS/WGT_EXEC.PDF).

Results
Demographic and metabolic syndrome characteristics of
study participants
Characteristics for the basic demographics and MetS with its
components are shown in Tables 1a and 1b, respectively. Overall, 26.2%
of participants were regular marijuana users and 24.0% were current
cigarette smokers (Table 1a). Among the different racial/ethnic groups,
people of other race/Multi-racials had the highest prevalence for
marijuana use (40.7%) with Asians having the least (7.6%). Among all
participants, the prevalence of other illicit drug use (cocaine, heroin or
methamphetamine) was 17.7% whilst multiracial had the highest
prevalence (28.7%). A higher proportion of Non-Hispanic Blacks
(7.8%) have had rehabilitation compared to Multiracial (7.4%).

Of the four criteria, ATP III and IDF classify more people as having
MetS (23.2% and 23.4%, respectively) and WHO criteria classify the
least (9.2%) and EGIR (8.6%) (Table 1b). This pattern is also seen for
MetS prevalence among marijuana users and cigarette smokers: the
proportion of MetS among marijuana users was 21.3% (IDF) and

Figure 1: Graphs showing the relationship between components of
metabolic syndrome and increasing years of marijuana use (Y-axis
shows the respective fitted values of components of MetS).

Components of metabolic syndrome with years of marijuana
use

The relationship between components of MetS and years of
marijuana use are shown in Figure 1. Curvilinear relationships between
years of marijuana use and components of MetS are apparent. The
relationship of systolic blood pressure (SBP), diastolic blood pressure
(DBP), waist circumference (WC), plasma triglycerides (TG)

Volume S11 • Issue 017 • S11-017

J Addict Res Ther, an open access journal
ISSN:2155-6105

44

Citation: Yankey BA, Rothenberg R, Strasser S, White KR, Okosun IS (2017) Relationship between Years of Marijuana Use and the Four Main
Diagnostic Criteria for Metabolic Syndrome among United States Adults. J Addict Res Ther S11: 017. doi: 10.4172/2155-6105.1000S11-

017

1.13) and by EGIR criteria, AOR was 1.06 (95% CI: 1.01, 1.11) (Table
3a).

and fasting blood glucose (FBG) with years of marijuana used tend to
be J-Shaped. This shows an initial decrease in values but eventual
increase. The relationship between plasma high density lipoprotein
cholesterol HDL-C and years of marijuana used was U-shaped. This
shows an initial decrease and eventual increase.

Each year of marijuana use showed AORs for hypertension as: 1.07
(95% CI: 1.03, 1.12) by ATP III and IDF, 1.05 (95% CI: 1.01, 1.09) by
WHO and 1.08 (95% CI: 1.03, 1.12) by EGIR All the applicable criteria
show increased odds for abdominal obesity: 1.06 (95% CI: 1.00, 1.11)
by ATP III, 1.09 (95% CI: 1.05, 1.14) by EGIR and 1.07 (95% CI: 1.01,
1.13) by IDF. For obesity the AOR was 1.03 (95% CI: 1.01, 1.06)
according to WHO. The AOR for having a high oral glucose tolerance
test level was 1.12 (95% CI: 1.07, 1.18) by WHO and EGIR.

Bivariate analysis of metabolic syndrome and its components
with years of marijuana use and cigarette smoking
By all the criteria, unadjusted analysis showed a universal increase
in odds of having MetS with every year of marijuana use. With every
year increase in marijuana use, the odds ratios (OR) for having MetS
are 1.06 (95% CI: 1.03, 1.08) for ATP III, 1.06 (95% CI: 1.04, 1.08) for
WHO, 1.05 (95% CI: 1.02, 1.08) for EGIR and 1.05 (95% CI: 1.03, 1.07)
for IDF (Table 2a). By all applicable criteria, for each year of marijuana
use, a significant increase in odds is observed for hypertension,
hyperglycemia, high oral glucose tolerance test levels,
hypertriglyceridemia, abdominal obesity and obesity.

Every year increase in smoking cigarette by this model, was
associated with AOR of 1.05 (95% CI: 1.01, 1.09) for hypertension by
WHO criteria. For abdominal obesity, the AOR was 0.97 (95% CI: 0.95,
0.99) by EGIR criteria (Table 3b).

Discussion
Duration of marijuana use seems to be a significant factor associated
with MetS. Its effect is small, but of the same order of magnitude or
possibly greater than the effect of years of cigarette smoking. It must be
noted that conventionally, cigarette smoking status has been used in
analysis, but we attempted assessing the effect of years of smoking
cigarette on MetS. Although current studies on marijuana use and MetS
show a protective effect of marijuana on glycemic factors, this may be
the result of not considering the years of using marijuana in cross
sectional analysis. All criteria, demonstrate that every year increase in
marijuana use is associated with at least 5% increase in odds of having
MetS. In relation to components of MetS, a general increase in odds is
observed with progress in years of using marijuana, however they vary
by significance.

The relationship with cigarette use shows increases in odds for MetS
which is only significant by ATP III. For hypertension, hyperglycemia
and high OGTT levels a significant increase in odds is demonstrated by
all the criteria (Table 2b).

Multivariate analysis
For every year of marijuana use, adjusted odds ratio (AOR) for
having MetS (controlling for years of smoking, gender, age, marriage,
education, country of birth, PIR, having health insurance, participating
in at least moderate physical activity, weekly alcohol intake, other illicit
drug use and undergoing rehabilitation) by ATP III and IDF criteria was
1.05 (95% CI: 1.02, 1.08). By WHO, AOR was 1.08 (95% CI: 1.04,

Diagnostic Criteria
Variable
ATP III

WHO

EGIR

IDF

Marijuana use1

1.06 (1.03-1.08)

1.06 (1.04-1.08)

1.05 (1.02-1.08)

1.05 (1.03-1.07)

Marijuana use1

1.06 (1.03-1.09)

1.09 (1.04-1.15)

1.08 (1.04-1.11)

1.06 (1.03-1.10)

Marijuana use1

1.04 (1.00-1.08)

1.04 (1.00-1.09)

1.04 (1.00-1.08)

1.04 (1.00-1.08)

1.03 (0.98-1.08)

1.04 (1.00-1.07)

1.07 (1.05-1.10)

1.07 (1.07-1.10)

Metabolic Syndrome

Hypertension

Hyperglycemia

Hyperinsulinemia
Marijuana use1

-

High OGTT
Marijuana use1

-

Hypertriglyceridemia
Marijuana use1

1.05 (1.03-1.07)

1.03 (1.01-1.06)

1.03 (1.01-1.08)

1.05 (1.03-1.07)

Marijuana use1

1.03 (1.00-1.06)

1.00 (0.97-1.03)

1.03 (1.00-1.05)

1.03 (1.00-1.06)

Low HDL-C

Abdominal Obesity

-
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Marijuana use1

1.03 (1.00-1.07)

1.07 (1.05-1.10)

1.03 (1.00-1.06)

-

-

-

-

Obesity
Marijuana use1
High Albumin/Creatinine Ratio

1.03 (1.01-1.05)
-

Marijuana use1

0.99 (0.96-1.02)

Table 2a: Unadjusted analysis of having metabolic syndrome and risky levels of components by the different criteria for each year of marijuana
use, bold values indicate significance at α<0.05, Marijuana use1 - each year of marijuana use among regular or non-regular marijuana users.
We observed different strengths in AORs for MetS with each year of
marijuana use based on the different criteria for Mets, but the same
direction of associations. Even though literature has discussed the
possibility of a common definition for MetS [15-17], this suggests that
the different criteria for metabolic syndrome may be comprehensive

and can produce unified relationships with respect to marijuana use.
This is irrespective of the fact that WHO and EGIR set predefined risk
factors on glucose or insulin impairment. However, WHO and EGIR
criteria, showed marked reductions in prevalence. This is primarily due
to the prequalifying criteria for glucose/insulin impairment.

Diagnostic Criteria
Variable
ATP III

WHO

EGIR

IDF

1.02 (1.01-1.05)

1.02 (0.98-1.05)

1.01 (0.99-1.04)

1.01 (0.99-1.03)

1.03 (1.00-1.06)

1.07 (1.03-1.12)

1.08 (1.04-1.11)

1.03 (1.00-1.06)

1.02 (1.00-1.03)

1.02 (1.00-1.04)

1.04 (1.00-1.08)

1.02 (1.00-1.03)

-

1.03 (0.99-1.07)

1.04 (1.00-1.07)

-

-

1.02 (1.00-1.05)

1.07 (1.05-1.10)

-

1.02 (1.01-1.04)

1.03 (1.00-1.05)

1.03 (1.01-1.06)

1.02 (1.01-1.04)

1.01 (0.99-1.02)

0.97 (0.94-1.01)

1.02 (1.00-1.05)

1.01 (0.99-1.02)

1.00 (0.98-1.02)

-

1.07 (1.05-1.10)

1.00 (0.98-1.02)

-

1.00 (0.98-1.02)

-

-

-

1.01 (0.99-1.03)

-

-

Metabolic Syndrome
Cig smoking1
Hypertension
Cig smoking1
Hyperglycemia
Cig smoking1
Hyperinsulinemia
Cig smoking1
High OGTT
Cig smoking1
Hypertriglyceridemia
Cig smoking1
Low HDL-C
Cig smoking1
Abdominal Obesity
Cig smoking1
Obesity
Cig smoking1
High Albumin/Creatinine Ratio
Cig smoking1

Table 2b: Unadjusted analysis of having metabolic syndrome and risky levels of components by the different criteria for every year of cigarette
smoking, bold values indicate significance at α<0.05, Cig smoking1-each year of cigarette use among regular or non-regular marijuana users.
Metabolic syndrome is a powerful tool for identifying people at risk
for CVD and diabetes [15]. It is important that research on marijuana
relationship with MetS and it
components. These findings could
provide a behavioral path to
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preventive and therapeutic interventions for CVD and diabetes [15] in
relation to marijuana use.

receptors and CB2 receptors. The ECS plays a role in regulation of
appetite and metabolism [18]. Modulation of the ECS affects the four
core attributes of MetS [19]. These effects are being studied for
management of obesity [20,21], dyslipidemia [21], atherosclerosis [22]
and insulin resistance [20,23]. Cannabinoids or cannabis extracts may
have therapeutic indications but, because absorption is erratic, the
pharmacodynamics is still under active investigation for therapeutic
purposes [24]. Arguments for recreational use of marijuana based on
research for therapeutic use may need re-evaluation.

Criteria of MetS is not settled, neither is the definition of marijuana
use. Metabolic syndrome is a complex condition and there may be
more factors intrinsic and extrinsic to MetS and marijuana use that
need attention. This study finds that prolonged use of marijuana is a
likely associated factor for MetS, glucose intolerance and hypertension.
Increased years of marijuana use are also associated with
hypertriglyceridemia but are significant using ATP III and IDF criteria.
Even though all the criteria use a plasma triglyceride cut off ≥ 150
mg/dl, WHO and EGIR do not account for the use of cholesterol
lowering medications and this could be a factor in the difference in
significance. The recreational use of marijuana may ultimately threaten
public health gains in the area of cardiovascular disease prevention. A
longitudinal study of the relationship between recreational marijuana
use and MetS concerning clinical factors and biological markers for all
the four core attributes of MetS: insulin resistance, visceral obesity,
atherogenic dyslipidemia and endothelial dysfunction [15] are exigent.

In Figure 1, initial reductions in blood pressure and glucose values
change to increases after about five years of use. This shows a probable
eventual deleterious effect on blood pressure and glycemic levels.
However, after about twenty years of using marijuana, low levels of
HDL-C tend to increase, which may allude an ultimate beneficial effect
on HDL-C. This further stresses the complex relationship between
cannabinoids and metabolic processes. All the applicable criteria show
that increased years of marijuana use is associated with abdominal
obesity. Active investigation of marijuana in long term metabolic
derangements is important. Criteria by IDF show higher odds for
abdominal obesity than ATP III. This is because IDF uses racial-ethnic
specific waist circumference.

The active constituent of marijuana, delta-9-tetrahydrocanabinol
(D-THC), acts on the endocannabinoid system (ECS), primarily CB1

Variable

ATP III

WHO

EGIR

IDF

1.05 (1.02, 1.08)

1.08 (1.04, 1.13)

1.06 (1.01, 1.11)

1.05 (1.02, 1.08)

1.01 (0.98, 1.04)

0.99 (0.95, 1.04)

1.00 (0.96, 1.04)

1.00 (0.97, 1.03)

Age 25+

2.70 (0.66,11.10)

0.67 (0.12, 3.78)

0.92 (0.19, 4.45)

1.01 (0.37, 2.78)

Males

0.78 (0.29, 2.09)

2.54 (0.98, 6.63)

1.29 (0.45, 3.64)

0.71 (0.27, 1.90)

Asians

1.37 (0.18,10.19)

1.72 (0.27,10.82)

0.98 (0.19, 5.14)

1.41 (0.24, 8.19)

Blacks

0.74 (0.33,1.66)

0.63 (0.13, 2.96)

0.59 (0.20, 5.08)

0.81 (0.36, 1.83)

M Americans2

0.63 (0.22, 1.80)

1.54 (0.55, 4.27)

2.02 (0.96, 4.23)

1.16 (0.31, 4.28)

Other Hispanics

0.22 (0.02, 2.55)

1.44 (0.33, 6.22)

1.01 (0.20, 5.08)

2.39 (0.40,14.24)

Other Race

0.99 (0.22, 4.48)

0.89 (0.18, 4.46)

0.69 (0.20, 2.40)

1.45 (0.39, 5.47)

Born in USA

3.87 (0.44,34.28)

3.04 (0.60,15.29)

4.08 (0.84,19.75)

5.53 (1.39,22.08)

Education

0.97 (0.59, 1.59)

1.26 (0.94, 1.71)

1.39 (0.80, 2.40)

0.98 (0.61, 1.58)

PIR3

0.93 (0.78, 1.10)

1.01 (0.65, 1.57)

0.91 (0.76, 1.09)

0.99 (0.81, 1.21)

Insured

1.25 (0.68, 2.27)

0.52 (0.25, 1.04)

0.66 (0.38, 1.15)

1.00 (0.52, 1.93)

1.17 (0.53, 2.58)

0.83 (0.30, 2.33)

1.75 (0.63, 4.83)

1.78 (0.54, 2.58)

1.17 (0.54, 2.51)

0.74 (0.31, 1.76)

0.85 (0.40, 1.79)

1.16 (0.53, 2.53)

Alcohol Intake5

1.84 (1.10, 3.08)

0.74 (0.28, 1.99)

0.95 (0.52, 1.74)

1.69 (1.04, 2.74)

Other drug use

0.92 (0.45, 1.89)

0.49 (0.21, 1.18)

0.39 (0.23, 0.64)

0.99 (0.46, 2.14)

Rehabilitation

1.01 (0.44, 2.33)

1.33 (0.50, 3.57)

1.66 (0.58, 4.77)

1.23 (0.55, 2.72)

Marijuana use1
Cigarette

smoking1

Married
Moderate

PA4

Table 3a: Multivariate analysis of metabolic syndrome with years of marijuana use by different criteria controlling for cigarette smoking and other
variables, 1-Each year increase in marijuana use or cigarette smoking; 2-Mexican American; 3-Family Income-to-Poverty Ratio; 4-At least
moderate physical activity (recreational); 5-Weekly, bold values indicates significant at α<0.05; ATP III-National Cholesterol Examination Panel,
Adult Treatment Panel III; EGIR: European Group for the Study of Insulin Resistance; IDF: International Diabetes Federation; WHO: World Health
Organization.
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In this study, non-significant varying relationships are observed with
each year of cigarette smoking and the different criteria for MetS. This
relationship could be explained by the combination of non- smokers and
past smokers. For marijuana use, all participants had at least used
marijuana before. The association of cigarette smoking status with
hypertension is established knowledge [25,26]. Increased years of
cigarette smoking was also associated with increased odds for high
OGTT levels (WHO and EGIR). Research has shown that diabetic
patients who continue to smoke have uncontrolled glucose levels even
with treatment [27]. Studies have long shown that nicotine from
cigarette smoking impairs glucose metabolism [28-30] and reflects as
high proportions of glycated hemoglobin, high OGTT and high fasting
insulin [31,32].

Strengths and limitations
Demographic, lifestyle, clinical, laboratory parameters and a large
nationally representative sample was obtained from NHANES data,
however this cross-sectional study estimates associations not risks.
Marijuana use was self-reported and the study may have a reporting bias
especially with information on illicit substance use as marijuana. We
initially controlled for the quantity of marijuana used but this did not
significantly affect the results and was excluded from the model.

ATP III

WHO

EGIR

IDF

Marijuana use1

1.07 (1.03, 1.12)

1.05 (1.01, 1.09)

1.08 (1.03, 1.12)

1.07 (1.03, 1.12)

Cigarette smoking1

1.02 (0.98, 1.05)

1.05 (1.02, 1.09)

1.02 (0.99, 1.05)

1.02 (0.98, 1.05)

Marijuana use1

1.02 (0.98, 1.07)

1.02 (0.98, 1.07)

1.02 (0.98, 1.07)

1.02 (0.98, 1.07)

Cigarette smoking1

1.00 (0.97, 1.03)

1.00 (0.97, 1.03)

1.00 (0.97, 1.03)

1.00 (0.97, 1.03)

Marijuana use1

-

1.01 (0.92, 1.11)

1.04 (0.99, 1.11)

-

Cigarette smoking1

-

1.00 (0.97, 1.03)

1.00 (0.96, 1.04)

-

Marijuana use1

-

1.12 (1.07, 1.18)

1.12 (1.07, 1.18)

-

Cigarette smoking1

-

0.99 (0.96, 1.03)

0.99 (0.96, 1.03)

-

Marijuana use1

1.04 (1.00, 1.07)

1.02 (0.98, 1.05)

1.02 (0.98, 1.05)

1.04 (1.00, 1.07)

Cigarette smoking1

1.01 (0.99, 1.03)

1.01 (0.98, 1.05)

1.01 (0.98, 1.05)

1.01 (0.99, 1.03)

Marijuana use1

1.03 (0.99, 1.07)

1.02 (0.98, 1.07)

1.04 (0.99, 1.08)

1.03 (0.99, 1.07)

Cigarette smoking1

0.99 (0.97, 1.02)

0.97 (0.92, 1.02)

0.98 (0.93, 1.03)

0.99 (0.97, 1.02)

Marijuana use1

1.06 (1.00, 1.11)

-

1.09 (1.05, 1.14)

1.07 (1.01, 1.13)

Cigarette smoking1

0.99 (0.97, 1.02)

-

0.97 (0.95, 0.99)

0.95 (0.95, 1.01)

Marijuana use1

-

1.03 (1.01, 1.06)

-

-

Cigarette smoking1

-

0.99 (0.97, 1.01)

-

-

Marijuana use1

-

0.96 (0.91, 1.01)

-

-

Cigarette smoking1

-

1.01 (0.97, 1.05)

-

-

Hypertension

Hyperglycemia

Hyperinsulinemia

High Oral Glucose Tolerance Test
level

Hypertriglyceridemia

Low HDL-C

Abdominal obesity

Obesity by (BMI)

High Albumin/ Creatinine ratio

Table 3b: Multivariate analysis of components of metabolic syndrome with each year of marijuana use and cigarette smoking by different criteria
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We did not control for diet, an important factor for MetS, however,
we controlled for factors important in dietary and health decisions as
income to poverty ratio (PIR), alcohol use, physical activity, health
insurance and education. For ethnic-specific waist circumference by
IDF, we classified NHBs as Europids based on ancestral genesis [33]
that the ancestry of Blacks or African-American are predominantly
Niger-Kordofanian (~71%), European (~13%) or other African (~8%)
populations [34]. All NHWs were classified using values for Americans
since distinctions based on the ethnic classification were unavailable.
We however controlled for place of birth to possibly account for these
differences.

2.

Conclusion

7.

3.
4.
5.
6.

Irrespective of the criteria for metabolic syndrome, each year of
marijuana use showed increased odds of having metabolic syndrome,
hypertension or high oral glucose tolerance test levels. Extended
duration of marijuana use could possibly increase the risk for the
development of metabolic syndrome. Longitudinal studies can show
this risk. Irrespective of the criteria for MetS, we estimated increased
odds of MetS with each year marijuana use. This may constitute an
important pathway between marijuana use and cardiovascular disease
in later life. The impact of duration of marijuana use should be
considered in assessing the relationships with MetS.

8.
9.
10.
11.
12.

Longitudinal research is required to define the true relationship
between marijuana use and metabolic syndrome. If a cardiovascular risk
is established, a good understanding of the pathogenesis of metabolic
syndrome and metabolic pathways of marijuana metabolites should be
laid out. This will help address any risk factors which may initiate and
facilitate CVD progression among marijuana users.
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CHAPTER 4.
Effect of marijuana use on cardiovascular and
cerebrovascular mortality: a study using the NHANES linked
mortality file
Abstract
Background: Reports associate marijuana use with cardiovascular emergencies. Studies relating
marijuana use to cardiovascular mortality are scarce. Recent advance towards marijuana use legalization
emphasizes the importance of understanding relationships between marijuana use and cardiovascular
deaths; the primary ranked mortality. Recreational marijuana is primarily smoked; we hypothesize that
like cigarette smoking, marijuana use will be associated with increased cardiovascular mortalities.
Design: Mortality follow-up.
Method: Data from 2011 public-use linked mortality file of National Center for Health Statistics, Centers
for Disease Control and Prevention was used. Participants were aged 20 years and above, and responded
to questions on marijuana use during the 2005 National Health and Nutrition Examination Survey. Only
participants eligible for mortality follow-up were included. We conducted cox proportional hazards
regression analyses to estimate hazard ratios for hypertension, heart disease and cerebrovascular mortality
due to marijuana use. We controlled for cigarette smoking and other relevant variables.
Results: Seventy-two and five-tenths percent of the 1213 eligible participants were presumed to be alive.
The total follow-up time was 19,569 person-years. Adjusted hazard ratios for death from hypertension
among marijuana users compared to non-marijuana users was 3.42 (95% CI: 1.20, 9.79) and for each year
of marijuana use was 1.04 (95% CI: 1.00, 1.07).
Conclusion: From our results, marijuana use increases the risk for hypertension mortality. Increased
duration of marijuana use is associated with increased risk of death from hypertension. Recreational
marijuana use potentially has cardiovascular adverse effects which needs further investigation.
Key words
THC, marijuana, cannabis, hypertension, cardiovascular mortality
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Introduction
Cardiovascular diseases (CVDs) rank first as cause of mortality worldwide and most are
preventable 1. Cardiovascular mortality encompasses death from diseases, emergencies or conditions
associated with heart and blood vessels 2. In 2013, one out of every four deaths in United States (US) was
due to heart disease (HD), stroke or other CVDs 3. Cardiovascular death rates have been declining in US
since year 2000 4 due to clinical and public health interventions including smoking cessation. Irrespective
of this decline 5, CVDs retain their lead as cause of mortality globally. Lifestyle modification including
smoking cessation, physical activity, healthy diet, maintaining normal body mass index, and avoidance of
harmful alcohol use reduce cardiovascular morbidity and mortality 6-8.
Reports associate marijuana use with cardiovascular emergencies. Marijuana like cigarette is
primarily smoked but contrary to marijuana, mortalities from CVDs due to cigarette smoking has been
studied extensively 9-11. Recent advance towards legalization of marijuana in US, necessitates the
determination of its association with cardiovascular mortality. The active constituent of marijuana, Delta9-tetrahydrocannabinol (THC), accounts for some cardiovascular effects of marijuana 12, 13. Marijuana
smoking increases heart rate from 20-100% for about two to three hours 14, causes postural hypotension,
fainting, ischemic stroke and disruption of cardiac functions 12, 15, 16. We hypothesize that similar to
cigarette smoking, recreational marijuana will be associated with increased cardiovascular mortalities.
Methods
We merged results of interviews in 2005 National Health and Nutrition Examination Survey
(NHANES) with 2011 public-use linked mortality file of the National Center for Health Statistics
(NCHS), Centers for Disease Control and Prevention (CDC) 17, since NHANES participants were
interviewed on marijuana use starting 2005. The NHANES assesses the health and nutritional status of
civilian noninstitutionalized US population. About 5000 nationally representative participants are selected
through complex, multistage probability sampling yearly. Interviews are conducted by physicians and
other healthcare professionals in participant’s homes and examinations conducted in a mobile center.
Mortality information on participants in NCHS public-use linked mortality file is obtained from death
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certificates or probabilistic matching from the National death index (NDI). Causes of death occurring in
US before 1999 were based on the 9th revision of International Statistical Classification of Diseases,
Injuries, and Causes of Death (ICD-9) guidelines and subsequently recoded into comparable ICD-10
rubrics, as cause of deaths occurring from 1999 are coded on the 10th (ICD-10) revision. Deaths are
classified as due to diseases of the heart (001), malignant neoplasms (002), chronic lower respiratory
disease (003), accidents-unintentional injuries (004), cerebrovascular diseases (005), Alzheimer’s diseases
(006), diabetes mellitus (007), influenza and pneumonia (008), nephritis, nephrotic syndrome and
nephrosis (009) and all other causes (010) with another coding for hypertension and diabetes deaths.
Those assumed alive, ineligible for follow up, or with cause of death unavailable are left un-coded.
We selected participants eligible for mortality follow up, aged 20 years and above who answered
“yes” or “no” to the question, “Have you ever used marijuana or hashish?” Participants who answered yes
were classified marijuana users and those who answered no, as non-marijuana users. Duration of
marijuana use was estimated by subtracting participant’s age at marijuana use initiation from the age at
2005 screen. Follow-up period for eligible participants was 1991-2011. This study collectively refers to
marijuana use, cigarette smoking and alcohol use as substance use. Participants who reported having
smoked at least 100 cigarettes in their lifetime and still smoke were classified current smokers, with those
who have ceased smoking as past-smokers. Those who never smoke nor smoked 100 cigarettes in lifetime
were classified non-smokers. High-risk drinking is defined in dietary guidelines for Americans 2015-2020
as consumption of four or more drinks any day or eight or more drinks weekly for women (five or more
drinks any day or 15 or more drinks weekly for men). Participants who confirmed ever having five or
more drinks almost every day at a point in life were classified as alcohol users. Participants reported their
age, gender, educational status and race/ethnicity and prior diagnosis of hypertension, angina, congestive
heart failure, heart attack or stroke by a doctor or other health professional.
Statistical Analysis
We estimated mortality rates and hazard ratio (HR) with 95% confidence intervals from Cox
proportional hazards regression, for hypertension, heart disease and cerebrovascular deaths among
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marijuana users and current cigarette smokers. Our main independent variables were marijuana use status
and years of marijuana use. We controlled for cigarette smoking (non-smokers as reference), gender
(female as reference), age ( 25 years and below as reference), race/ethnicity (Non-Hispanic Whites as
reference), having health insurance (not having health insurance as reference), alcohol use (not having
had five drinks or more on some days in life as reference), diagnosis of hypertension (no diagnosis of
hypertension as reference) or CVD: angina, heart attack, congestive heart failure or coronary heart disease
(no diagnosis of CVD as reference), education and body mass index (BMI), were controlled using
continuous increasing level. Age was dichotomized as 25 years and below, or above 25 years. Research
shows the age cut off point associated with illicit substance use, smoking and heavy alcohol consumption
is 25 years 18. Interaction factor between smoking status and marijuana use status was not significant in
the survival model, so the interaction factor was excluded. We estimated cumulative hazard for
hypertension, heart and cerebrovascular disease mortality by marijuana use or cigarette smoking status
over the 20 year period of follow up. Nelson-Aalen curves estimate cumulative hazard functions of
censored data 19. The follow-up was right censored at the end of 2011.

Results
Demographic characteristics, marijuana use and cigarette smoking
Total eligible participants were 1213 with one observation ending on or before entry and 72.5%
presumed alive. Person-years follow up was 19,569. Average age at entry of participants was 37.7±11.2.
Average BMI for all participants was 29.0±7.0, for marijuana users, 28.6±7.1 and for cigarette smokers,
27.7±6.9. Demographic distribution is shown in Table 1. Among all 1213 participants, 34.3% neither use
marijuana nor smoke cigarettes, 20.9% use only marijuana, 20.0% use marijuana & smoke cigarettes,
15.6% use marijuana & are past-smokers, 4.8% are past-smokers and 4.4% smoke only cigarettes.
Average duration of marijuana use was 11.5±12.8 years and 10.1±13.8 years for cigarette smoking.
Diagnosis of hypertension or other cardiovascular diseases
Twenty and a third percent of marijuana users compared to 20.6% of non-marijuana users had
prior diagnosis of hypertension. Among current smokers, 21.8% had prior diagnosis of hypertension

54

compared to 23.4% of past-smokers and 18.7% of never smokers. Prevalence for prior diagnosis of any
other CVDs was 3.8% among marijuana users and 3.6% for non-marijuana users, 6.1% for current
smokers, 5.7% past-smokers and 1.9% for never smokers. Distribution of hypertension, heart and
cerebrovascular mortality is shown in Table 1.
Mortality incidence rates and ratios
For all-cause mortality among marijuana users, incidence rate ratio was 1.29 (95% CI: 1.03, 1.61)
and among current smokers 1.16 (95% CI: 0.90, 1.48). Mortality incidence rates by marijuana use and
cigarette smoking stratified by cause of death are shown in Table 2.
Unadjusted and adjusted hazard ratios
Unadjusted hazard ratio for hypertension mortality among marijuana users compared to nonmarijuana users was 1.86 (95% CI: 0.95, 3.66). Unadjusted HRs are shown in Table 3. For HD mortality,
unadjusted HR was 1.21 (95% CI: 0.76, 1.92) among marijuana users compared to non-marijuana users
and 1.01 (95% CI: 0.99, 1.03) for each year of marijuana use. For cerebrovascular disease mortality, all
unadjusted HRs were non-significant for marijuana use and cigarette smoking (not shown in Table).
Adjusted HRs for hypertension mortality among marijuana users compared to non-marijuana
users was 3.42 (95% CI: 1.20, 9.79), and for each year of marijuana use was 1.04 (95% CI: 1.00, 1.07)
(Table 3). All adjusted HRs for HD and cerebrovascular mortality showed non-significant estimates in
this model for marijuana use and cigarette smoking in this model most likely due to sample size. Adjusted
HR for HD mortality was: a) 1.09 (95% CI: 0.63, 1.88) for marijuana users compared to non-marijuana
users and b) 1.00 (95% CI: 0.98, 1.02) for each year of marijuana use (Not shown in Table).
Cumulative Hazard Curves
Nelson-Aalen cumulative hazard estimates show that marijuana users have a higher risk for
hypertension mortality than non-marijuana users (Figure 1A). For hypertension mortality, there are more
flattened areas for smokers; non-smokers seem to have a higher risk. Cumulative hazard for all-cause
mortality is higher among marijuana users and cigarette smokers than their counterparts (Figure 1B).
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Discussion
Marijuana users had an increased risk of hypertension mortality even after controlling for prior
diagnosis of hypertension. Opiates have more deleterious consequences on the cardiovascular system than
marijuana 20, but hypertensive crisis following marijuana use has been described 21, also cases of cardiac
infarction and stroke following marijuana use among normotensives and people lacking history of
cardiovascular diseases have however been described 21-23. Increase in risk for hypertension, HD or
cerebrovascular disease mortality associated with cigarette use was not significant, largely due to the
small sample size (n < 30) of mortalities among cigarette smokers under investigation. The hazardous
effect of cigarette smoking on cardiovascular system has however been largely demonstrated in studies 9
and is established knowledge. Also, our study focuses on marijuana use, and initial selection criteria was
based on responses to marijuana use among adults. Our assumption that marijuana use or cigarette
smoking continues throughout the period of follow up, may not be so. Taking into consideration the
availability of smoking cessation programs, these behaviors may change with time, from participation in
an intervention. Specific marijuana use cessation interventions are yet to be documented. Also use of
cocaine/heroin/methamphetamine or participation in rehabilitation was not statistically relevant in our
model and was excluded. We however controlled for relevant demographic factors. The observed large
confidence intervals for marijuana use estimates can also be attributed to sample size.
Within our limitations, our results however support a possible increased risk of mortality from
CVDs related to marijuana use. Taking into consideration results of study by Aronow, W.S. and J.
Cassidy 24, it is possible that the cardiovascular risk associated with marijuana use and prolonged years of
marijuana use is even greater than the risk already described for cigarette use in studies.
Delta-9-Tetrahydrocannabinol (THC) acts primarily on the endocannabinoid system which
regulates behavior, metabolism and cardiovascular function. The endocannabinoid system consists of
neuro-modulatory lipids (primarily the endogenous cannabinoid anandamide and 2-arachidonylglycerol),
their metabolites and cannabinoid receptors CB1 and CB2. Cannabinoid receptors are distributed in the
central nervous system, cardiovascular system and peripheral tissues. Cannabinoids including the
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phytocannabinoid THC, exert sympathetic stimulation. Delineated cardiovascular effects of THC are
increased heart rate, increased supine blood pressure, orthostatic hypotension 14, increased cardiac output,
reductions in left ventricular ejection time16 and increases in venous carboxyhemoglobin levels24 which
cause unhealthy cardiovascular and cerebrovascular outcomes.
The 2020 goal of American heart association is to improve cardiovascular health of all Americans
by 20%, and reduce mortality from CVDs and stroke by 20%. Public health and clinical interventions
have helped to promote the life’s simple seven indicators of good cardiovascular health: blood pressure
control, increased physical activity, healthy diet, total cholesterol control, healthy weight, blood glucose
control and smoking cessation which contributes to plummeting age standardized death rates from CVDs
since 2009 25. Smoking is still the leading cause of preventable disease and death, and since recreational
marijuana is primarily smoked, its use may contribute to increases in morbidities and mortalities. Factors
of interest include effects of marijuana use on cardiovascular mortality among the youth and people with
existing chronic conditions. The youth, especially those aged 18-25 years are more liable to substance use
26

and adults are more likely to live with chronic conditions. This expands the demographic coverage of

poor health consequences of marijuana use. In the interest of individual health, population health and
lowering costs associated with healthcare, education on the adverse effects of recreational marijuana use
should be a priority as recommendations and advancements are made towards its legalization.

Conclusion
Marijuana use increases the risk of hypertension mortality. Longer years of marijuana use
increases risk of death from hypertension. This cardiovascular risk associated with marijuana use, may be
greater than the cardiovascular risk already established for cigarette smoking. We are not disputing the
possible medicinal benefits of standardized cannabis formulations; however, recreational use of marijuana
should be approached with caution. It is possible that discouraging recreational marijuana use may
ultimately impact reductions in mortality from cardiovascular causes. A purposeful longitudinal study
modeled with inclusion of listed relevant limitations is recommended.
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Table 1: Sociodemographic characteristics of participants, showing overall prevalence (%) and
mortality rates (%) from hypertension, heart diseases and cerebrovascular disease.

Variables

Participants

Total
Mortality HBP

HD

CBV

Age ≤ 25years
Age >25years
Total
Male
Female
Total
Non-Hispanic Whites
Non-Hispanic Blacks
Mexican Americans
Other Hispanics
Other Race
Total
< 9th grade
9th - 11th grade
High school graduate
Some College/Associate degree
≥ College graduate
Total
Marijuana users
Non-marijuana users
Total
Current cigarette smokers
Past-cigarette smokers
Non-cigarette smokers
Total
Alcohol use
No Alcohol use
Total

Sample
226
987
1213
550
663
1213
579
286
246
45
57
1213
89
166
277
394
286
1212
686
527
1213
296
248
669
1213
190
882
1072

Sample
63
269
332
168
164
332
162
76
63
11
20
332
20
43
76
112
81
332
204
138
332
89
74
169
332
55
243
298

%
22.2
23.0
22.9
23.2
22.6
22.9
26.5
19.7
22.2
18.2
10.0
22.9
30.0
20.9
21.1
19.6
28.4
22.9
22.5
23.4
22.9
15.7
27.0
24.8
22.9
29.1
22.6
23.8

%
11.1
6.3
7.2
4.8
9.8
7.2
7.4
10.5
3.2
0
10.0
7.2
5.0
9.3
7.9
8.0
4.9
7.2
7.4
7.0
7.2
9.0
9.5
5.3
7.2
7.3
6.2
6.4

%
18.6
81.4
100.0
45.3
54.7
100.0
47.7
23.6
20.3
3.7
4.7
100.0
7.3
13.7
22.9
32.5
23.6
100.0
56.5
43.5
100.0
24.4
20·4
55.2
100.0
17.7
82.3
100.0

%
9.5
12.6
12.1
8.3
15.9
12.1
14.8
7.9
7.9
27.3
10.0
12.1
15.0
7.0
7.9
15.2
13.6
12.1
13.7
9.4
12.1
10.1
14.9
11.8
12.1
10.9
11.1
11.1

HBP, Hypertension HD, Heart Disease CBV, Cerebrovascular disease
Note: Mortality rates shown are row percentages based on total mortality but do not add up to 100%
because mortality rates of other diseases are not shown.
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Table 2: Incidence estimates for mortality from hypertension, heart disease and cerebrovascular
disease by substance use among study participants

Cause of mortality
Hypertension
Incidence rate in exposed/1000
Incidence rate in unexposed/1000
Incidence rate in population/1000
Incidence rate ratio
Attributable fraction in exposed
Attributable fraction in population

Marijuana
2.57
1.39
2.04
1.85 (0.92, 4.00)
46.0%
32.1%

Heart disease
Incidence rate in exposed/1000
Incidence rate in unexposed/1000
Incidence rate in population/1000
Incidence rate ratio
Attributable fraction in exposed
Attributable fraction in population

4.22
3.47
3.88
1.22 (0.75, 2.00)
17.8%
10.8%

Cerebrovascular Disease
Incidence rate in exposed/1000
Incidence rate in unexposed/1000
Incidence rate in population/1000
Incidence rate ratio
Attributable fraction in exposed
Attributable fraction in population

1.37
1.04
1.23
1.32 (0.54, 3.43)
24.4%
15.2%
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Table 3: Unadjusted and adjusted analysis showing hazard ratios for hypertension mortality
among (a) marijuana users and (b) each year of marijuana use

Substance use and demographic
factors
A)
Marijuana user
Current smoker
Former smoker
Alcohol user
Body mass index
Age >25years
Education
Male
Blacks
Mexican Americans
Other Hispanics
Other Race
Have health insurance
Diagnosed with hypertension
Diagnosed with a CVD
B)
Each year of marijuana use
Current smoker
Former smoker

Unadjusted hazards ratio
(95% Confidence interval)

Adjusted hazards ratio
(95% Confidence interval)

1.86 (0.95, 3.66)
1.06 (0.48, 2.33)
1.56 (0.75, 3.25)
1.03 (0.43, 2.50)
1.03 (1.00, 1.08)*
1.29 (0.54, 3.08)
1.19 (0.90, 1.57)
0.67 (0.35, 1.29)
0.51 (0.21, 1.24)
0.49 (0.19, 1.28)
1.58 (0.48, 5.25)
0.92 (0.22, 3.89)
2.66 (1.04, 6.79)*
0.86 (0.38, 1.93)
2.18 (0.67, 7.06)

3.42 (1.20, 9.79)*
1.06 (0.40, 2.77)
1.33 (0.57, 3.10)
0.95 (0.37, 2.45)
1.05 (1.01, 1.10)*
1.25 (0.42, 3.67)
1.00 (0.70, 1.43)
0.72 (0.35, 1.49)
0.42 (0.14, 1.27)
0.91 (0.28, 2.94)
2.51 (0.54, 11.63)
1.23 (0.29, 5.35)
2.24 (0.75, 6.72)
0.81 (0.32, 2.06)
1.94 (0.42, 8.97)

1.03 (1.00, 1.05)*
1.06 (0.48, 2.33)
1.56 (0.75, 3.25)

1.04 (1.00, 1.07)*
1.14 (0.43, 3.01)
1.35 (0.57, 3.20)

CVD, Cardiovascular disease (angina, heart attack, congestive heart failure or coronary heart disease)
Note: In Model A, hazard ratios are estimated based on substance use status, In Model B based on each
year of marijuana use controlling for the same variables in Model A
*P<0.05
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Figure 1: Nelson-Aalen cumulative hazard estimate of mortality from (A) hypertension and (B) allcauses associated with marijuana use and cigarette smoking. Y-axis shows cumulative hazard rate
and X-axis shows follow-up time.
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CHAPTER 5.
Summary of three studies
Smoking seems to find a way of sustaining its popular social practice despite evidence of its
detrimental effects on health. After several years of use, the deleterious effect of tobacco on health
and economic growth cannot be overstated and the impact of public health measures towards
smoking cessation and successes cannot be understated. The current inclination towards legalization
of marijuana questions the possibility of a replay of the journey with tobacco.
The use of marijuana in adults is also increasing especially among adults aged 25 years and
above. Schedule I substances under the Federal Controlled Substances Act (CSA) are considered as
having a high potential for abuse and not having any currently accepted medical use in treatment,
consequently its use is reserved for very limited circumstances. The current move towards
reclassification of marijuana as a legal substance places an urgent call to investigate the relationship of
marijuana with cardiovascular diseases; the number one cause of morbidities and mortalities.
In our first study, we assessed the relationship between marijuana use, cigarette smoking and
metabolic syndrome (as well as components of metabolic syndrome) among adults in the United
States, with emphasis on marijuana use. Our hypothesis was that in the United States, adults who use
marijuana or/and tobacco are more likely to have unhealthy levels of the factors of metabolic
syndrome and ultimately metabolic syndrome. We conducted multiple logistic regression analyses
using data from the 2011–2012 United States National Health and Nutrition Examination Survey
(NHANES). We classified metabolic syndrome using the definition by National Cholesterol Education
Program, Adult Treatment Panel III (NCEP, ATP III) 2004 modification, which adapts the International
Diabetes Federation (IDF) definition for hypertension and diabetes. The ATP III criteria is commonly
used because of its clinical applicability. We estimated odds ratios for metabolic syndrome and its
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components among participants who reported that they have smoked marijuana regularly for at least
a year and still use marijuana. We also estimated odds ratios for metabolic syndrome and its
components among current smokers. In the multivariate model, we included years of marijuana use
and years of cigarette smoking and adjusted for factors endogenous and exogenous to marijuana use
and relevant to metabolic syndrome: age, gender, race/ethnicity, education, income to poverty ratio,
having health insurance, marriage, physical activity, alcohol use, use of other substances of abuse,
participation in rehabilitation, joints of marijuana used and cigarette packs smoked. We estimated
increased odds ratios for metabolic syndrome (OR 1.05; 95% CI: 1.01, 1.09), and hypertension (OR
1.04; 95% CI: 1.01, 1.07) with each year of marijuana use. We also estimated increased odds ratios for
hypertension (OR 1.03; 95% CI: 1.00, 1.06) and hyperglycemia (OR 1.03; 95% CI: 1.01, 1.05) with each
year of cigarette smoking. Consistent with research, those who reported using marijuana showed a
decrease odd ratio for metabolic syndrome (OR 0.23; 95% CI: 0.06, 0.90) compared to those who do
not use marijuana. The finding that years of marijuana use is increases the odds for metabolic
syndrome and hypertension stresses a possible factor that has been missed in assessing the marijuana
use with metabolic syndrome. In separate analysis among those who smoke cigarette and those who
use marijuana compared to their counterparts, this increase in odds ratios was still evident, and there
was also an increased odds ratio for hypertriglyceridemia with each year of marijuana use (OR 1.03;
95% CI: 1.01, 1.06) and each year of cigarette use (OR 1.04 (1.02, 1.06).
Because metabolic syndrome has different criteria, in our second study, we assessed the
relationship between metabolic syndrome and marijuana use based on the four common criteria by
National Cholesterol Education Program, Adult Treatment Panel III (NCEP, ATP III), World Health
Organization (WHO), European Group for the study of Insulin Resistance (EGIR), and International

67

Diabetes Federation (IDF). The different criteria used could also impact the results of the relationship
between metabolic syndrome and marijuana use. Our hypothesis was that the definition used for
metabolic syndrome may change the estimates of the associations between marijuana use and
metabolic syndrome. We estimated the prevalence of marijuana use and cigarette smoking by race
and conducted multiple logistic regression to estimate odds ratios. In the multivariate model, we
controlled for age, gender, race, education, marital status, income to poverty ratio (PIR), participation
in at least moderate physical activity, days of alcohol use per week, other recreational substance use
(methamphetamine, heroin or cocaine) and participation in rehabilitation. Each year increase in
marijuana use showed increased odds ratios for metabolic syndrome by all the four criteria: 1.05 (95%
CI: 1.02, 1.08) using National Cholesterol Education Program Adult Treatment Panel III (ATP III) criteria,
1.08 (95% CI: 1.04, 1.13) using International Diabetes Federation (IDF) and 1.05 (95% CI: 1.04, 1.13)
using World Health Organization (WHO) or European Group for the study of Insulin Resistance (EGIR)
criteria. Each year of marijuana use, showed increased odds ratio for hypertension for all the criteria:
1.7 (95% CI: 1.03, 1.12) using ATP III or IDF criteria, 1.05 (95% CI: 1.01, 1.09) using WHO criteria, and
1.8 (95% CI: 1.03, 1.12) using EGIR criteria. The ATP III, EGIR and IDF criteria for metabolic syndrome
include increased waist circumference (abdominal obesity) in defining metabolic syndrome. All the
criteria showed increased odds ratios for abdominal obesity: 1.06 (95% CI: 1.00, 1.11) for ATP III, 1.09
(95% CI: 1.05, 1.14) for EGIR and 1.07 (95% CI: 1.01, 1.13) for IDF. The World Health organization and
European Group for the study of Insulin Resistance have oral glucose tolerance test as part of the
components for metabolic syndrome. Each year of marijuana use was associated with increased oral
glucose tolerance test levels; OR 1.12 (95% CI: 1.07, 1.18). We also fitted residuals of each component
of metabolic syndrome (systolic blood pressure, diastolic blood pressure, waist circumference, plasma
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glucose, serum triglycerides and serum high density lipoprotein cholesterol) with years of marijuana
use. This graphs showed an initial decrease in values but eventual increase in systolic blood pressure
(SBP), diastolic blood pressure (DBP), waist circumference (WC), plasma triglycerides (TG) and fasting
blood glucose (FBG) with progress in years of marijuana use. However, the relationship between
plasma high density lipoprotein cholesterol (HDL-C) and years of marijuana used showed an initial
decrease and eventual increase.
Metabolic syndrome is associated with increased risk for cardiovascular morbidities and
mortalities. With our estimates of increased odds of metabolic syndrome relative to duration
marijuana use, we assessed the relationship of marijuana use with cardiovascular mortality. We used
data from 2011 public-use linked mortality file of National Center for Health Statistics, Centers for
Disease Control and Prevention and linked them to participants aged 20 years and above who
responded to questions on marijuana use during the 2005 National Health and Nutrition Examination
Survey and were eligible for mortality follow-up. Because recreational marijuana is primarily smoked;
our hypothesis was that: like cigarette smoking, marijuana use will be associated with increased
cardiovascular mortalities. We conducted cox proportional hazards regression analyses to estimate
hazard ratios for hypertension, heart disease and cerebrovascular mortality due to marijuana use. We
controlled for cigarette smoking, alcohol use, age, education, gender, race, having health insurance,
diagnosis of a cardiovascular disease (angina, congestive heart failure, heart attack or stroke) or
hypertension. Marijuana use increased the risk for hypertension mortality. Adjusted hazard ratios for
death from hypertension among marijuana users compared to non-marijuana users was 3.42 (95% CI:
1.20, 9.79) and for each year of marijuana use was 1.04 (95% CI: 1.00, 1.07).
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Results of our study consistently show that marijuana use is associated with metabolic
syndrome and detrimental cardiovascular health. Increased years of marijuana use was associated with
increased odds of hypertension, increased values of systolic and diastolic blood pressures as well as
increased risk for hypertension mortality. Contrary to research that marijuana use may be safe, our
research shows that prolonged use of marijuana is associated with detrimental cardiovascular health.
The endocannabinoid system plays an important role in metabolic regulation and current studies
should explore the pathways associated with cardio-metabolic function and health.
Our research is primarily cross sectional and exploratory, but the results point to the urgency
and importance of investigating the relationship between marijuana use and cardio-metabolic health
for the benefit of the public who believe that recreational marijuana use is probably not harmful to
health, especially during an era where marijuana legalization is gaining support.

Public health significance of study
Metabolic syndrome is an emerging public health problem which may reach global epidemic
levels because of changing lifestyles towards a more westernized lifestyle. Smoking is a major lifestyle
associated with cardiovascular problems and hence metabolic syndrome. It is projected that metabolic
syndrome may overtake smoking as a known risk factor for cardiovascular problems especially heart
diseases. With the increasing support for legalizing marijuana use, it is important to demonstrate the
relationship of marijuana with metabolic syndrome. If marijuana is found to be a risk factor for
components of metabolic syndrome and cardiovascular disease at the same magnitude as cigarette
smoking or even more, public health gains in cardiovascular disease prevention stand threatened. This
is especially dependent on the likelihood of increased marijuana use with its legalization.
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Metabolic syndrome can be controlled with healthy lifestyle. Even though the focus has been
on healthy diet and participation in physical activity, smoking cessation should be an integral part of
metabolic syndrome management. If marijuana use is found to have detrimental effect on metabolic
activity and cardiovascular health, it will be important to develop intervention plans to reduce
recreational marijuana use. The management and control of metabolic syndrome requires the effort of
individuals at risk, families, communities, health care providers and health care systems.
The goal of healthy people 2020 on substance use is to reduce substance abuse to protect the
health, safety, and quality of life for all, especially children (Health et al., 2000). Substance use has a
major impact on the quality of life, on families, on communities, on nations and on health systems.
Substance use especially marijuana use is on the ascendancy among adults. Increasing age is already
an independent factor for several chronic diseases and coupling this with the detrimental effects of
substance use can pose a significant health burden. Substance use carries economic, social, mental
and public health problems. In 2005, about 22 million Americans had a drug use or alcohol problem
with 95% of them unaware of their drug use or alcohol problem. About 24.8% of those who know their
problem and seek treatment are not successful at obtaining treatment.
Heart disease, stroke and other cardiovascular disease, are highly prevalent in the United
States and pose significant economic and health burden. The goal of healthy people 2020 for
cardiovascular health is to improve cardiovascular health and quality of life through prevention,
detection, and treatment of risk factors for heart attack and stroke. This includes early identification
and prompt treatment of heart attacks and strokes, interventions to prevent repetition of
cardiovascular events and ultimately reduction in cardiovascular mortalities. Risk factors listed as
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modifiable for cardiovascular disease are high blood pressure, high cholesterol, diabetes, unhealthy
diet, physical inactivity, overweight and obesity and cigarette smoking.
Evidence suggests that, rates of cardiovascular morbidity and mortality among the US
population would decline significantly with major interventions on, and improvements in lifestyle
concerning diet, physical activity, control of high blood pressure and cholesterol, appropriate aspirin
use and smoking cessation with emphasis on bridging disparities (Barr, 2016) .
Healthy people 2020 aims increase overall cardiovascular health in the US population, reduce
coronary heart disease and stroke mortalities, reduce the proportion of persons in the population with
hypertension, reduce the proportion of adults with high total blood cholesterol levels and mean levels
of total blood cholesterol among the population, increase the proportion of adults who are advised by
health care providers on cholesterol lowering management, healthy lifestyles as well as use of aspirin
where indicated for people with elevated low density lipoprotein cholesterol. Healthy People 2020
aims to reduce the disease burden of diabetes mellitus and improve the quality of life for all persons
who have, or are at risk for diabetes mellitus. Some objectives towards this goal relevant to our study
include reducing the annual number of new cases of diagnosed diabetes in the population and
reducing the rates of cardiovascular deaths among people diagnosed with diabetes. The association of
marijuana use with hyperglycemia in our study makes marijuana use an important indicator of the
rates of incident diabetes which needs further investigation. If this relationship is established,
education on the harms of marijuana to glycemic factors and subsequent interventions to reduce
incidence of diabetes through reductions in rates of marijuana use will be relevant.
Our research seeks to raise awareness of the health impact on the co-occurrence of these
factors among populations and the detrimental effects it can cause on health, and to document the
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urgency of investigating the relationship of recreational marijuana use among populations with
cardiovascular morbidity and mortality. The finding that increasing years of marijuana use is associated
with increased odds for metabolic syndrome and mortality from hypertension is an observation that
calls for urgent investigation to delineate the mechanisms underlying marijuana use and cardiovascular
health, especially among a nation with increasing support for legalization of marijuana use. About one
in every three adults in the US has hypertension and only about 50% of them have their blood pressure
under control (S. S. Yoon, Carroll, & Fryar, 2015).
Primary prevention methods for sustaining cardiovascular health are highly effective. Stressing
on lifestyle changes to improve and preserve cardiovascular health is a major activity of public health.
Prevention efforts on substance use which carry cardiovascular risk are thus very important. Some of
the Healthy People 2020 objectives towards reducing substance use include: increasing the proportion
of adolescents aged 12 to 17 years who perceive great risk with substance abuse, increasing the
proportion of adolescents who disapprove of trying marijuana or hashish once or twice by ten percent,
increase the proportion of persons who received specialty treatment for abuse or dependence in the
past year from 16% as 2008 to 17·6% by 2020 among those who need alcohol and/or illicit drug
treatment, and to reduce illness, disability, and death related to tobacco use and secondhand smoke
exposure.
The objectives on substance use prevention are strongly related to the constructs of social
cognitive theory; the theoretical basis for explaining substance use. It is important that the populace
build a solid cognitive disposition on substance use based on the information available on its effects
on health especially during the early years of life. This can help improve self-efficacy and ultimately
prevent the use of substances that can be detrimental to health. With increase in the prevalence of
substance use
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among adults, it is important the education on substance use is targeted toward adults as well,
especially those who already have existing chronic diseases.
Demonstrating the true effects of recreational substance use (especially those that are easily
accessible and seem harmless) on health will help prevent substance use and protect the health of
the public. The framework for ending tobacco use epidemic outlined by Healthy People 2020 can be
applied to marijuana use prevention if research establishes marijuana use as detrimental to health.
Policies as outlined for tobacco prevention may include comprehensive marijuana-free policies,
abstinence and cessation programs on marijuana use and access to these programs, hard-hitting
anti marijuana media campaigns, funding for marijuana control programs and research, measures of
controlling access to marijuana based on its eventual decriminalization, and limiting advertising and
promotion aimed at adolescents.
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Appendices
‘‘Have you ever
used marijuana?’’

Yes

No

‘‘Have you smoked marijuana or hashish at least
once a month for more than a year?’

(Never marijuana
users)

Yes

No

(Regular
marijuana users)

(Non-Regular
marijuana users)

‘‘How old
were you the first time you
used marijuana or hashish?’’

Figure 1.1 Measurement of independent variable (marijuana use)

Figure 1.2 Measurement of independent variable (cigarette smoking)
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Figure 2.1 Definition of metabolic syndrome by four common criteria
Chart adapted from Scott M. Grundy, James I. Cleeman, et al., AHA/NHLBI Scientific Statement: Diagnosis
and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and
Blood Institute Scientific Statement Circulation. 2005;112:17 2735-2752
ALB/CR
ATP (III)
BMI
EGIR
FPI
HDL-C
IDF
IFG
IGT
LIS
T2DM
TG
OGTT
WHO

– Albumin creatinine ratio
– National Cholesterol Education Program Adult Treatment Panel III
– Body mass index
– European Group for the Study of Insulin Resistance
– Fasting plasma Insulin
– High density lipoprotein cholesterol
– International Diabetes Federation
– Impaired fasting glucose
– Impaired glucose tolerance
– Low insulin sensitivity
– Type 2 diabetes mellitus
– Triglycerides
– Oral glucose tolerance test
– World Health Organization
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Figure 3.1 Chart showing selection of participants for merging and mortality follow-up

Figure 3.2 Distribution of participants by substance use
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